_pmid,_doi,_publicationTitle,_year,_context,_confidence,_verdict,_usageType,targetAntigen,hostOrganism,clonality,cloneId,uniprotId,reactiveSpecies,conjugate
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,Anti-tyrosine hydroxylase (Rabbit polyclonal) EMD Millipore Cat#: AB152 RRID: AB_390204 IHC (1:1000),0.9,Accept,Experimental Usage,tyrosine hydroxylase,Rabbit,Polyclonal,,,,Non-conjugated
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,Anti-tyrosine hydroxylase (mouse monoclonal) ImmunoStar Cat#: 22941 RRID: AB_572268 IHC (1:1000),0.9,Accept,Experimental Usage,tyrosine hydroxylase,Mouse,Monoclonal,,,,Non-conjugated
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,Anti-GFP (mouse polyclonal) Aves Cat#: GFP-1020 RRID: AB_10000240 IHC (1:1000),0.9,Accept,Experimental Usage,GFP,Mouse,Polyclonal,,,,Non-conjugated
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,Alexa Fluor 488-conjugated donkey anti-chicken IgY F(ab')two fragment Jackson ImmunoResearch Cat#: 703-546-155,0.85,Accept,Experimental Usage,chicken IgY,Unknown,Secondary,,,,Alexa Fluor 488
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,Alexa Fluor 647-conjugated donkey anti-mouse IgG Fab fragment Jackson ImmunoResearch Cat#: 711-607-003,0.85,Accept,Experimental Usage,mouse IgG,Unknown,Secondary,,,,Alexa Fluor 647
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,"Immunohistochemical stain for TRIM23 (ThermoFisher, PA5-34624, 1:150, rabbit polyclonal)",0.95,Accept,Experimental Usage,TRIM23,Rabbit,Polyclonal,,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,"Immunohistochemistry for histone 3 lysine trimethylation (H3K27 me3) was performed using rabbit monoclonal antibodies (C36B11, 1:50 dilution; Cell Signaling Technology)",0.95,Accept,Experimental Usage,H3K27me3,Rabbit,Monoclonal,,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,"Immunohistochemical staining for Cleaved-caspase 3 at 1:500 (Cell Signaling Technology, Danvers, MA)",0.9,Accept,Experimental Usage,Cleaved-caspase 3,,,,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,prediluted Ki67 (790–4286; Ventana),0.9,Accept,Experimental Usage,Ki67,,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,"serially sectioned (5 μm) and immunostained with GFAP, Iba1, Ki67, CD3, Midkine, GAP43, CD34, Factor XIIIa, SOX10, neurofilament-200, and Col1a2",0.9,Accept,Experimental Usage,GFAP,,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,"serially sectioned (5 μm) and immunostained with GFAP, Iba1, Ki67, CD3, Midkine, GAP43, CD34, Factor XIIIa, SOX10, neurofilament-200, and Col1a2",0.9,Accept,Experimental Usage,Iba1,,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,"serially sectioned (5 μm) and immunostained with GFAP, Iba1, Ki67, CD3, Midkine, GAP43, CD34, Factor XIIIa, SOX10, neurofilament-200, and Col1a2",0.9,Accept,Experimental Usage,Ki67,,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,"serially sectioned (5 μm) and immunostained with GFAP, Iba1, Ki67, CD3, Midkine, GAP43, CD34, Factor XIIIa, SOX10, neurofilament-200, and Col1a2",0.9,Accept,Experimental Usage,SOX10,,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,"Primary RGCs, hippocampal neurons, DRG neurons, sh NF1 Schwann cells, and hiPSC-sensory neurons were immunostained with appropriate primary (RGCs: Rbpms, Tuj-1",0.9,Accept,Experimental Usage,Rbpms,,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,"Primary RGCs, hippocampal neurons, DRG neurons, sh NF1 Schwann cells, and hiPSC-sensory neurons were immunostained with appropriate primary (RGCs: Rbpms, Tuj-1",0.9,Accept,Experimental Usage,Tuj-1,,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,"DRG neurons: Peripherin, ISL1, Tuj-1",0.9,Accept,Experimental Usage,Peripherin,,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,"DRG neurons: Peripherin, ISL1, Tuj-1",0.9,Accept,Experimental Usage,ISL1,,,,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,"The primary antibodies used in this study were P-cadherin (R&D Systems, AF761), DCT (PEP8h; gift from Dr. Vincent Hearing)",0.9,Accept,Experimental Usage,P-cadherin,Unknown,Unknown,,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,"DCT (PEP8h; gift from Dr. Vincent Hearing, National Institutes of Health)",0.9,Accept,Experimental Usage,DCT,Unknown,Monoclonal,,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,"K14 (biotin-labeled, Thermo, clone LL002), LacZ (Abcam, ab9361), GFP/YFP (Aves, 1020)",0.9,Accept,Experimental Usage,K14,Unknown,Monoclonal,,,,Biotin
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,"K14 (biotin-labeled, Thermo, clone LL002), LacZ (Abcam, ab9361), GFP/YFP (Aves, 1020)",0.9,Accept,Experimental Usage,LacZ,Unknown,Unknown,,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,"LacZ (Abcam, ab9361), GFP/YFP (Aves, 1020), Krox20 (Covance, PRB-236P)",0.9,Accept,Experimental Usage,GFP/YFP,Unknown,Unknown,,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,"GFP/YFP (Aves, 1020), Krox20 (Covance, PRB-236P), and KIT (Cell Signaling, 3074)",0.9,Accept,Experimental Usage,Krox20,Unknown,Unknown,,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,"Krox20 (Covance, PRB-236P), and KIT (Cell Signaling, 3074). For immunofluorescent staining",0.9,Accept,Experimental Usage,KIT,Unknown,Unknown,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,"neurofibromin – Bethyl (Bethyl, Cat# A300-140A, primary 1:500, secondary 1:2000)",0.95,Accept,Experimental Usage,neurofibromin,,Unknown,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,"H12 (Santa Cruz Biotechnology, Cat# sc-376886, primary 1:500, secondary 1:2000)",0.95,Accept,Experimental Usage,neurofibromin,,Unknown,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,"iNF-07E (gifted by iNFiXion Bioscience, Biointron, Cat# B21900201, primary 1:500, secondary 1:2000)",0.95,Accept,Experimental Usage,neurofibromin,,Unknown,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,"pERα S118 (Sigma, Cat# SAB450399)",0.9,Accept,Experimental Usage,pERα S118,,Unknown,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,"pERK T202/Y204 (Cell Signaling Technology, Cat#9101L)",0.9,Accept,Experimental Usage,pERK T202/Y204,,Unknown,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,"pAKT S473 (Cell Signaling Technology, Cat#9271L)",0.9,Accept,Experimental Usage,pAKT S473,,Unknown,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,"β-tubulin (Cell Signaling Technology, Cat#2146, primary 1:500, secondary 1:2000)",0.9,Accept,Experimental Usage,β-tubulin,,Unknown,,,,
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,labeled overnight at room temperature with the following conjugated primary antibodies: Brn3a-FITC,0.85,Accept,Experimental Usage,Brn3a,,,,,,FITC
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,"labeled overnight at room temperature with the following conjugated primary antibodies: Brn3a-FITC, RBPMS-APC",0.85,Accept,Experimental Usage,RBPMS,,,,,,APC
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,Thy1.1-APC (ganglion cell marker),0.85,Accept,Experimental Usage,Thy1.1,,,,,,APC
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,Caspase9-FITC (apoptosis marker),0.85,Accept,Experimental Usage,Caspase9,,,,,,FITC
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,Ki67-FITC (proliferation marker),0.85,Accept,Experimental Usage,Ki67,,,,,,FITC
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,"Cmyc-FITC, Oct4-APC (stemness markers)",0.85,Accept,Experimental Usage,Cmyc,,,,,,FITC
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,"Cmyc-FITC, Oct4-APC (stemness markers)",0.85,Accept,Experimental Usage,Oct4,,,,,,APC
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,NeuN-APC (neuronal marker),0.85,Accept,Experimental Usage,NeuN,,,,,,APC
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,"Every 5th section was stained with CD45-PE, IBA1-FITC (immune cell marker)",0.85,Accept,Experimental Usage,CD45,,,,,,PE
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,"CD45-PE, IBA1-FITC (immune cell marker)",0.85,Accept,Experimental Usage,IBA1,,,,,,FITC
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,Every 6th section was stained with GFAP-PE (Muller cells marker),0.85,Accept,Experimental Usage,GFAP,,,,,,PE
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,STEM121-FITC (human cell marker),0.85,Accept,Experimental Usage,STEM121,,,,,,FITC
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"stained with anti-HLA-DR Percp-cy5.5 (eBioscience, 0.015 µg/test, San Diego, CA, USA)",0.9,Accept,Experimental Usage,HLA-DR,Unknown,Unknown,,,Human,Percp-cy5.5
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"anti-CD33 APC (eBioscience, 0.125 µg/test)",0.9,Accept,Experimental Usage,CD33,Unknown,Unknown,,,Human,APC
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"anti-CD11b FITC antibodies (eBioscience, 0.5 µg/test)",0.9,Accept,Experimental Usage,CD11b,Unknown,Unknown,,,Human,FITC
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"primary antibodies against CD9 (Proteintech, 60232-1-Ig, Wuhan, China)",0.9,Accept,Experimental Usage,CD9,Unknown,Unknown,,,Human,Non-conjugated
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"CD81 (Proteintech, 66866-1-Ig)",0.9,Accept,Experimental Usage,CD81,Unknown,Unknown,,,Human,Non-conjugated
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"TOMM20 (Proteintech, 11802-1-AP)",0.9,Accept,Experimental Usage,TOMM20,Unknown,Polyclonal,,,Human,Non-conjugated
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"HSP90 (Proteintech, 13171-1-AP)",0.9,Accept,Experimental Usage,HSP90,Unknown,Polyclonal,,,Human,Non-conjugated
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"AKT (CST, #9272S, Danvers, MA, USA)",0.9,Accept,Experimental Usage,AKT,Unknown,Unknown,,,Human,Non-conjugated
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"p-AKT (CST, #4051S)",0.9,Accept,Experimental Usage,p-AKT,Unknown,Unknown,,,Human,Non-conjugated
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"ERK (CST, #4695)",0.9,Accept,Experimental Usage,ERK,Unknown,Unknown,,,Human,Non-conjugated
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"p-ERK (CST, #9101S)",0.9,Accept,Experimental Usage,p-ERK,Unknown,Unknown,,,Human,Non-conjugated
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,"Western blot analyses were performed using anti-total and anti-phospho Erk1/2 (Cell Signaling, Danvers, MA, USA) antibodies",0.85,Accept,Experimental Usage,Erk1/2,,,,,,
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,"Western blot analyses were performed using anti-total and anti-phospho Erk1/2 (Cell Signaling, Danvers, MA, USA) antibodies",0.85,Accept,Experimental Usage,phospho-Erk1/2,,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,"Primary antibodies (Cell Signaling Technology) used for Western blotting were FLAG (rabbit, 14793)",0.9,Accept,Experimental Usage,FLAG,Rabbit,Unknown,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,"Primary antibodies (Cell Signaling Technology) used for Western blotting were V5 (rabbit, 13202)",0.9,Accept,Experimental Usage,V5,Rabbit,Unknown,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,"Primary antibodies (Cell Signaling Technology) used for Western blotting were HA (rabbit, 3724)",0.9,Accept,Experimental Usage,HA,Rabbit,Unknown,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,Western blots to verify protein expression levels were run on Tris acetate or Bolt gels and probed with a series of antibodies: pEGFR (Cell Signaling 3777),0.9,Accept,Experimental Usage,pEGFR,,Unknown,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,vinculin (Cell Signaling 19301),0.9,Accept,Experimental Usage,vinculin,,Unknown,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,KRAS (Sigma/Novus Biologicals WH0003845M1/H0003845M1),0.9,Accept,Experimental Usage,KRAS,,Monoclonal,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,The primary antibodies and dilutions used were goat anti-collagen IV (Millipore AB769; 1:500),0.95,Accept,Experimental Usage,collagen IV,Unknown,Unknown,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,mouse anti-MyHC type 1 (DSHB BA-D5; 1:500),0.95,Accept,Experimental Usage,MyHC type 1,Mouse,Monoclonal,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,mouse anti-MyHC type 2A (DSHB SC-71; 1:200),0.95,Accept,Experimental Usage,MyHC type 2A,Mouse,Monoclonal,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,rabbit anti-laminin (Sigma-Aldrich L9393; 1:500),0.95,Accept,Experimental Usage,laminin,Rabbit,Unknown,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,mouse anti-Pax7 (DSHB Pax7; 1:10),0.95,Accept,Experimental Usage,Pax7,Mouse,Monoclonal,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,mouse anti-myosin heavy chain (Sigma-Aldrich 05-716; 1:1000),0.95,Accept,Experimental Usage,myosin heavy chain,Mouse,Unknown,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,anti-beta III tubulin antibody (Sigma-Aldrich AB9354; 1:500),0.95,Accept,Experimental Usage,beta III tubulin,Unknown,Unknown,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,anti-perilipin A/B antibody (Sigma-Aldrich p1873; 1:250),0.95,Accept,Experimental Usage,perilipin A/B,Unknown,Unknown,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,Antibodies used were rabbit anti-PPARG (Cell Signaling Technology 2443),0.95,Accept,Experimental Usage,PPARG,Rabbit,Unknown,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,rabbit anti-phosphor (pThr172) AMPKa (Cell Signaling Technology 2535),0.95,Accept,Experimental Usage,phosphor (pThr172) AMPKa,Rabbit,Unknown,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,rabbit anti-AMPKα (Cell Signaling Technology 2532),0.95,Accept,Experimental Usage,AMPKα,Rabbit,Unknown,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,mouse anti-β-actin (Cell Signaling Technology 58169),0.95,Accept,Experimental Usage,β-actin,Mouse,Unknown,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,mouse anti-β-tubulin (Sigma-Aldrich T8328),0.95,Accept,Experimental Usage,β-tubulin,Mouse,Unknown,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,rabbit anti-phosphor (s235/236) S6 (Cell Signaling Technology 4858),0.95,Accept,Experimental Usage,phosphor (s235/236) S6,Rabbit,Unknown,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,mouse anti-MyHC type 2B (DSHB BF-F3),0.95,Accept,Experimental Usage,MyHC type 2B,Mouse,Monoclonal,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,"rabbit anti-phosphor (Ser473) AKT (Cell Signaling, #9271; 1:1000)",0.95,Accept,Experimental Usage,phosphor (Ser473) AKT,Rabbit,Unknown,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,"rabbit anti-phospho (Ser1101) IRS-1 (Cell Signaling, #2385; 1:1000)",0.95,Accept,Experimental Usage,phospho (Ser1101) IRS-1,Rabbit,Unknown,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,"rabbit anti-phospho (Ser636/639) IRS-1 (Cell Signaling, #2388; 1:1000)",0.95,Accept,Experimental Usage,phospho (Ser636/639) IRS-1,Rabbit,Unknown,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,"incubated with anti-DIG-Fab antibody coupled to alkaline phosphatase (Roche, 11093274910)",0.95,Accept,Experimental Usage,DIG-Fab,Unknown,Unknown,,,,alkaline phosphatase
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,"N-, K-, and H-RAS were detected with a 1:100 dilution of murine monoclonal pan-RAS antibody (BD Biosciences, San Diego, CA, USA, product #610002).",0.95,Accept,Experimental Usage,RAS,Mouse,Monoclonal,,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,"N-RAS was detected with a 1:400 dilution of a rabbit polyclonal N-RAS antibody (Santa Cruz, CA, USA, product #sc-519).",0.95,Accept,Experimental Usage,N-RAS,Rabbit,Polyclonal,,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,"RAB5A was detected with a 1:250 dilution of a rabbit polyclonal RAB5A antibody (Santa Cruz, Santa Cruz, CA, USA, product #sc-309).",0.95,Accept,Experimental Usage,RAB5A,Rabbit,Polyclonal,,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,"Non-prenylated RAP1A was detected with a 1:250 dilution of a goat polyclonal RAP1A antibody (Santa Cruz, product #1482).",0.95,Accept,Experimental Usage,RAP1A,Unknown,Polyclonal,,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,"GAPDH was detected with a 1:1000 dilution of rabbit polyclonal antibody to GAPDH (Cell Signaling, Boston, MA, USA, product #2118).",0.95,Accept,Experimental Usage,GAPDH,Rabbit,Polyclonal,,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,"β-actin was detected with a 1:25,000 dilution of murine monoclonal antibody to β-actin (Sigma, St. Louis, MI, USA, product #A5441).",0.95,Accept,Experimental Usage,β-actin,Mouse,Monoclonal,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,"FFPE tissue blocks were collected for each fresh-frozen tumor which underwent multiomic profiling and were used for pathology review, IHC (MYF-4, H3K7me3, S100, and Sox10)",0.85,Accept,Experimental Usage,H3K27me3,,Unknown,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,"FFPE tissue blocks were collected for each fresh-frozen tumor which underwent multiomic profiling and were used for pathology review, IHC (MYF-4, H3K7me3, S100, and Sox10)",0.85,Accept,Experimental Usage,MYF-4,,Unknown,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,"FFPE tissue blocks were collected for each fresh-frozen tumor which underwent multiomic profiling and were used for pathology review, IHC (MYF-4, H3K7me3, S100, and Sox10)",0.85,Accept,Experimental Usage,S100,,Unknown,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,"FFPE tissue blocks were collected for each fresh-frozen tumor which underwent multiomic profiling and were used for pathology review, IHC (MYF-4, H3K7me3, S100, and Sox10)",0.85,Accept,Experimental Usage,Sox10,,Unknown,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,Additional IHC (HMB45 and Melan-A) was performed to exclude melanoma,0.85,Accept,Experimental Usage,HMB45,,Unknown,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,Additional IHC (HMB45 and Melan-A) was performed to exclude melanoma,0.85,Accept,Experimental Usage,Melan-A,,Unknown,,,,
PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,"cells were incubated with 2 µg/mL rabbit anti-human S100 antibody (DAKO, Glostrup, Denmark)",0.9,Accept,Experimental Usage,S100,Rabbit,Unknown,,,Human,Non-conjugated
PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,"cells were incubated with 2 µg/mL anti-human CD90 antibody (Dianova, Hamburg, Germany)",0.85,Accept,Experimental Usage,CD90,Unknown,Unknown,,,Human,Non-conjugated
PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,10 µg/mL secondary fluorescein isothiocyanate (FITC)-conjugated anti-rabbit antibody (DAKO),0.85,Accept,Experimental Usage,rabbit IgG,Unknown,Secondary,,,Rabbit,FITC
PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,2 µg/mL secondary FITC-conjugated goat anti-mouse IgG (DAKO),0.85,Accept,Experimental Usage,mouse IgG,Unknown,Secondary,,,Mouse,FITC
PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,Schwann cells were incubated with antibody against s-100b (Sigma) as the primary overnight at 1:400 ratio,0.85,Accept,Experimental Usage,s-100b,Unknown,Unknown,,,Human,
PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,"treated with anti-rabbit IgG as secondary (Alexa Fluro 594, Invitrogen) for 2 hours at 1:1000 ratio",0.85,Accept,Experimental Usage,rabbit IgG,Unknown,Secondary,,,,Alexa Fluor 594
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,"1:400 anti-Hmga2 (Biocheck), 1:100 anti-beta-Catenin (BD bioscience), 1:100 anti-Ck19 (Abcam)",0.9,Accept,Experimental Usage,HMGA2,Unknown,Unknown,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,"1:400 anti-Hmga2 (Biocheck), 1:100 anti-beta-Catenin (BD bioscience), 1:100 anti-Ck19 (Abcam)",0.9,Accept,Experimental Usage,beta-Catenin,Unknown,Unknown,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,"1:400 anti-Hmga2 (Biocheck), 1:100 anti-beta-Catenin (BD bioscience), 1:100 anti-Ck19 (Abcam)",0.9,Accept,Experimental Usage,CK19,Unknown,Unknown,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,"1:1000 anti-Sox9 (Millipore); 1:10,000 anti-Hsp90 (BD Biosciences)",0.9,Accept,Experimental Usage,SOX9,Unknown,Unknown,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,"1:1000 anti-Sox9 (Millipore); 1:10,000 anti-Hsp90 (BD Biosciences)",0.9,Accept,Experimental Usage,HSP90,Unknown,Unknown,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,1:1000 anti-pErk (Cell Signaling),0.9,Accept,Experimental Usage,p-ERK,Unknown,Unknown,,,,
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,"Mouse anti-Flag (Sigma-Aldrich) was used at 1∶20,000",0.9,Accept,Experimental Usage,Flag,Mouse,Unknown,,,,
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,guinea-pig anti-Merlin [8] was used at 1∶5000,0.85,Accept,Experimental Usage,Merlin,Unknown,Unknown,,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,...followed by a 12-min incubation with the CONFIRM anti-Ki67 (clone 30-9) rabbit monoclonal primary antibody (Roche)...,0.95,Accept,Experimental Usage,Ki67,Rabbit,Monoclonal,,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,"...followed by an incubation with polyclonal anti-collagen XV (Sigma-Aldrich, HPA017913, 1:1000)...",0.95,Accept,Experimental Usage,collagen XV,,Polyclonal,,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,"...or in-house monoclonal anti-collagen XVIII (ref. [ 46 ], DB144-N2, 7 µg/ml) primary antibody...",0.95,Accept,Experimental Usage,collagen XVIII,,Monoclonal,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,"K1 (BioLegend, 905601, 1:100)",0.9,Accept,Experimental Usage,K1,Unknown,Unknown,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,"NF1 (Santa Cruz; sc-67, 1:100)",0.9,Accept,Experimental Usage,NF1,Unknown,Unknown,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,"H3K27Me3 (Cell Signaling, 9733 S, 1:500)",0.9,Accept,Experimental Usage,H3K27Me3,Unknown,Unknown,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,"S100 (DAKO, Z0311, 1:5000)",0.9,Accept,Experimental Usage,S100,Unknown,Unknown,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,"NF1 (Santa Cruz; H-12, 1:100)",0.9,Accept,Experimental Usage,NF1,Unknown,Unknown,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,"LUMICAN (Santa Cruz; sc-166871, 1:200)",0.9,Accept,Experimental Usage,LUMICAN,Unknown,Unknown,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,precoated with indicated doses of anti-CD3 Ab (eBioscience; cat. no. 16-0031-86),0.9,Accept,Experimental Usage,CD3,Unknown,Unknown,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,anti-CD28 mAb (eBioscience; cat. no. 16-0281-85),0.9,Accept,Experimental Usage,CD28,Unknown,Monoclonal,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,FITC-anti-CD69 mAb (eBioscience; cat. no. 11-0691-85; 1:100),0.9,Accept,Experimental Usage,CD69,Unknown,Monoclonal,,,,FITC
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,CD4 [eBioscience; cat. no. 17-0042-83; 1:100],0.9,Accept,Experimental Usage,CD4,Unknown,Unknown,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,CD8 [Lifetech; cat. no. A15836; 1:100],0.9,Accept,Experimental Usage,CD8,Unknown,Unknown,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,FoxP3 [eBioscience; cat. no. 12-57773-80; 1:100],0.9,Accept,Experimental Usage,FoxP3,Unknown,Unknown,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,B220 [eBioscience; cat. no. 11-0452-85; 1:100],0.9,Accept,Experimental Usage,B220,Unknown,Unknown,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,CD45 [eBioscience; cat. no. 25-0451-82; 1:100],0.9,Accept,Experimental Usage,CD45,Unknown,Unknown,,,,
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,"stained with monoclonal anti-human MIA antibody (R&D Systems, McKinley Place NE, Minneapolis) diluted at 1:40",0.9,Accept,Experimental Usage,MIA,Unknown,Monoclonal,,,Human,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"Immunofluorescence staining was performed using the following primary antibodies: GFAP (Sigma; St. Louis, MO)",0.9,Accept,Experimental Usage,GFAP,Unknown,Unknown,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"AQP4, NG2, O4, LHX2 (Chemicon International; Temecula, CA)",0.9,Accept,Experimental Usage,AQP4,Unknown,Unknown,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"AQP4, NG2, O4, LHX2 (Chemicon International; Temecula, CA)",0.9,Accept,Experimental Usage,NG2,Unknown,Unknown,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"AQP4, NG2, O4, LHX2 (Chemicon International; Temecula, CA)",0.9,Accept,Experimental Usage,O4,Unknown,Unknown,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"AQP4, NG2, O4, LHX2 (Chemicon International; Temecula, CA)",0.9,Accept,Experimental Usage,LHX2,Unknown,Unknown,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"APC (Calbiochem; San Diego, CA)",0.9,Accept,Experimental Usage,APC,Unknown,Unknown,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"FOXG1, FOXP2 (Abcam; Cambridge, MA)",0.9,Accept,Experimental Usage,FOXG1,Unknown,Unknown,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"FOXG1, FOXP2 (Abcam; Cambridge, MA)",0.9,Accept,Experimental Usage,FOXP2,Unknown,Unknown,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"HOXB3 (Santa Cruz Biotechnology; Santa Cruz, CA)",0.9,Accept,Experimental Usage,HOXB3,Unknown,Unknown,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,GLAST (a gift from Dr. Watanabe; (Shibata et al. 1997)),0.85,Accept,Experimental Usage,GLAST,Unknown,Unknown,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"Immunohistochemical staining was performed using GFAP (Zymed, San Francisco, CA)",0.9,Accept,Experimental Usage,GFAP,Unknown,Unknown,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"Ki-67 (BD Pharmingen, San Diego, CA) antibodies followed by Vectastain ABC development",0.9,Accept,Experimental Usage,Ki-67,Unknown,Unknown,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"Rabbit anti-NF1GRP-D (Santa Cruz Biotechnology, Santa Cruz, CA) was used at a 1:200 dilution to detect neurofibromin expression",0.9,Accept,Experimental Usage,NF1GRP-D,Rabbit,Unknown,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"α-tubulin (Sigma, St. Louis, MO) was employed for normalization and densitometric analysis",0.9,Accept,Experimental Usage,α-tubulin,Unknown,Unknown,,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,The expression of the DDK-tagged transcript was validated by Western blot using anti-DDK antibodies,0.85,Accept,Experimental Usage,DDK tag,Unknown,Unknown,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,Anti-Merlin monoclonal antibody 4B5 was made by W. Ip,0.9,Accept,Experimental Usage,Merlin,Unknown,Monoclonal,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,Horseradish peroxidase (HRP) conjugated an antibody specific for GFP (cat. no. 600–103-215) was from Rockland,0.9,Accept,Experimental Usage,GFP,Unknown,Unknown,,,,HRP
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,specific for RFP (cat no. ab34767) was from Abcam,0.9,Accept,Experimental Usage,RFP,Unknown,Unknown,,,,HRP
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,Antibody specific for YAP1 was from Cell Signaling Inc.,0.85,Accept,Experimental Usage,YAP1,Unknown,Unknown,,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,"Antibodies were from Cell Signaling Technology (Danvers, U.S.A.) (rabbit anti-HA; mouse anti-HA; 9B11 mouse anti-myc)",0.85,Accept,Experimental Usage,HA,Rabbit,Unknown,,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,"Antibodies were from Cell Signaling Technology (Danvers, U.S.A.) (rabbit anti-HA; mouse anti-HA; 9B11 mouse anti-myc)",0.85,Accept,Experimental Usage,HA,Mouse,Unknown,,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,"Antibodies were from Cell Signaling Technology (Danvers, U.S.A.) (rabbit anti-HA; mouse anti-HA; 9B11 mouse anti-myc)",0.9,Accept,Experimental Usage,myc,Mouse,Monoclonal,,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,"Invitrogen (mouse anti-V5), Sigma-Aldrich (St. Louis, U.S.A.) (mouse and rabbit anti-FLAG)",0.85,Accept,Experimental Usage,V5,Mouse,Unknown,,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,"Sigma-Aldrich (St. Louis, U.S.A.) (mouse and rabbit anti-FLAG), and LI-COR Biosciences",0.85,Accept,Experimental Usage,FLAG,Mouse,Unknown,,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,"Sigma-Aldrich (St. Louis, U.S.A.) (mouse and rabbit anti-FLAG), and LI-COR Biosciences",0.85,Accept,Experimental Usage,FLAG,Rabbit,Unknown,,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,"LI-COR Biosciences (Lincoln, U.S.A.) (goat anti-rabbit 680 nm and goat anti-mouse 800 nm conjugates)",0.85,Accept,Experimental Usage,rabbit,Unknown,Secondary,,,,680 nm
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,"LI-COR Biosciences (Lincoln, U.S.A.) (goat anti-rabbit 680 nm and goat anti-mouse 800 nm conjugates)",0.85,Accept,Experimental Usage,mouse,Unknown,Secondary,,,,800 nm
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,"Phosphorylated ERK Thr202/Tyr204 (catalog #4376), phosphorylated Akt Ser473 (#9271) and phosphorylated S6 Ser235/236 (#2211) (all from Cell Signaling, Beverly, MA)",0.9,Accept,Experimental Usage,phosphorylated ERK Thr202/Tyr204,Unknown,Unknown,,,,
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,"Phosphorylated ERK Thr202/Tyr204 (catalog #4376), phosphorylated Akt Ser473 (#9271) and phosphorylated S6 Ser235/236 (#2211) (all from Cell Signaling, Beverly, MA)",0.9,Accept,Experimental Usage,phosphorylated Akt Ser473,Unknown,Unknown,,,,
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,"Phosphorylated ERK Thr202/Tyr204 (catalog #4376), phosphorylated Akt Ser473 (#9271) and phosphorylated S6 Ser235/236 (#2211) (all from Cell Signaling, Beverly, MA)",0.9,Accept,Experimental Usage,phosphorylated S6 Ser235/236,Unknown,Unknown,,,,
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,"Coverslips were permeabilized and probed with anti-γH2AX Ser139 antibody (Millipore), followed by anti-rabbit AlexaFluor 488 secondary antibody",0.9,Accept,Experimental Usage,γH2AX Ser139,Unknown,Unknown,,,,
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,followed by anti-rabbit AlexaFluor 488 secondary antibody (Molecular Probes),0.9,Accept,Experimental Usage,rabbit IgG,Unknown,Secondary,,,,Alexa Fluor 488
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,"HIF-1α, BECLIN1, BIM, BCL-xL, β-tubulin, Ferritin HC and transferrin receptor-1 (TfR1/CD71; Santa Cruz Biotechnology Inc., Santa Cruz, CA)",0.85,Accept,Experimental Usage,HIF-1α,Unknown,Unknown,,,,
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,"BNIP3 (Sigma, St. Louis, MO)",0.85,Accept,Experimental Usage,BNIP3,Unknown,Unknown,,,,
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,"HIF-1α, BECLIN1, BIM, BCL-xL, β-tubulin, Ferritin HC and transferrin receptor-1 (TfR1/CD71; Santa Cruz Biotechnology Inc., Santa Cruz, CA)",0.85,Accept,Experimental Usage,BECLIN1,Unknown,Unknown,,,,
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,"LC3 (Abgent, San Diego, CA)",0.85,Accept,Experimental Usage,LC3,Unknown,Unknown,,,,
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,"GAPDH, BCL-2 and PUMA (Cell Signaling, Danvers, MA)",0.85,Accept,Experimental Usage,GAPDH,Unknown,Unknown,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,"rabbit anti-p53 (NCL-p53-CM5p, 1:1000, Leica Biosystems)",0.95,Accept,Experimental Usage,p53,Rabbit,Unknown,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,"mouse anti-Ki67 (550609, 1:500, BD Pharmingen)",0.95,Accept,Experimental Usage,Ki67,Mouse,Monoclonal,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,"rabbit anti-Olig2 (AB9610, 1:2000, EMD Millipore)",0.95,Accept,Experimental Usage,Olig2,Rabbit,Unknown,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,"Guinea pig anti-Olig2 (1:10000, a kind gift of home-made antibody from Dr. B. Novitch)",0.9,Accept,Experimental Usage,Olig2,Unknown,Unknown,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,"mouse anti-GFAP (556330, 1:2000, BD Pharmingen)",0.95,Accept,Experimental Usage,GFAP,Mouse,Monoclonal,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,"rabbit anti-Pten (9559S, 1:1000, Cell Signaling)",0.95,Accept,Experimental Usage,Pten,Rabbit,Unknown,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,"rabbit anti-p-S6 (5364S, 1:2000, Cell Signaling)",0.95,Accept,Experimental Usage,p-S6,Rabbit,Unknown,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,"rat anti-BrdU (ab6326, 1:500, Abcam)",0.95,Accept,Experimental Usage,BrdU,Unknown,Unknown,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,"rabbit anti-p-Erk (9101S, 1:2000, Cell Signaling)",0.95,Accept,Experimental Usage,p-Erk,Rabbit,Unknown,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,"PAX8 Proteintech, 10336-1-AP 1:2000 Overnight, RT Citrate buffer, pH 6.0",0.9,Accept,Experimental Usage,PAX8,Unknown,Unknown,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,"Ac-alpha-Tubulin Santa Cruz, sc-23950 1:2000 Overnight, RT Citrate buffer, pH 6.0",0.9,Accept,Experimental Usage,Ac-alpha-Tubulin,Unknown,Unknown,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,"KI67 Monosan, MONX10283 1:2000 Overnight, RT Citrate buffer, pH 6.0",0.9,Accept,Experimental Usage,KI67,Unknown,Unknown,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,"Cytokeratin-8 Santa Cruz, sc-101459 1:50 Overnight, RT Citrate buffer, pH 6.0",0.9,Accept,Experimental Usage,Cytokeratin-8,Unknown,Unknown,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,"GFP Life Technologies, A11122 1:1000 Overnight, RT Citrate buffer, pH 6.0",0.9,Accept,Experimental Usage,GFP,Unknown,Unknown,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,"Cleaved Caspase-3 (D175) Cell Signaling Technology, #9661L 1:500 Overnight, RT Citrate buffer, pH 6.0",0.9,Accept,Experimental Usage,Cleaved Caspase-3,Unknown,Unknown,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,"mouse anti-γH2A.X primary antibody (1:500, Millipore, clone JBW301)",0.9,Accept,Experimental Usage,γH2A.X,Mouse,Monoclonal,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,"probed with antibodies directed against p53 (sc-6243, 1:250, Santa Cruz Biotechnology)",0.9,Accept,Experimental Usage,p53,Unknown,Unknown,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,"GAPDH (LN2100751, 1:1000, Labned)",0.9,Accept,Experimental Usage,GAPDH,Unknown,Unknown,,,,
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,incubated in primary antibodies against ABCC1 (Abcam ab24102) and S100 (Dako Z0311) at 1:50 and 1:400 dilution,0.95,Accept,Experimental Usage,ABCC1,Unknown,Unknown,,,,
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,incubated in primary antibodies against ABCC1 (Abcam ab24102) and S100 (Dako Z0311) at 1:50 and 1:400 dilution,0.95,Accept,Experimental Usage,S100,Unknown,Unknown,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,"Primary antibodies used in this study: Rabbit anti-GFP, Thermo Fisher, Cat. # A6455 (1/1000)",0.95,Accept,Experimental Usage,GFP,Rabbit,Unknown,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,"Mouse anti-mCherry, Abcam, Cat. # ab125096 (1:500)",0.95,Accept,Experimental Usage,mCherry,Mouse,Unknown,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,"mouse anti-glutamine synthetase (GS), Sigma-Aldrich, Cat. #MAB302 (1/500)",0.95,Accept,Experimental Usage,glutamine synthetase,Mouse,Monoclonal,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,"Alexa Flour 555 Donkey anti Mouse-IgG (H+L), Thermo Fisher Cat. # A31570 (1:500)",0.95,Accept,Experimental Usage,Mouse IgG,Unknown,Secondary,,,,Alexa Fluor 555
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,"Alexa flour 555 Donkey anti Rabbit IgG (H+L), Thermo Fisher, Cat # A31572 (1:500)",0.95,Accept,Experimental Usage,Rabbit IgG,Unknown,Secondary,,,,Alexa Fluor 555
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,Alexa Flour 488 donkey anti mouse Thermo Fisher Cat. # A21202 (1:500),0.95,Accept,Experimental Usage,Mouse IgG,Unknown,Secondary,,,,Alexa Fluor 488
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,Alexa Flour 488 goat anti rabbit Thermo Fisher Cat. # A11008 (1:500),0.95,Accept,Experimental Usage,Rabbit IgG,Unknown,Secondary,,,,Alexa Fluor 488
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,"Primary antibodies used in western blot analysis were: mouse anti-β-actin, mouse anti-α-tubulin, and mouse anti-α-smooth muscle actin (α-SMA), all from Sigma-Aldrich",0.9,Accept,Experimental Usage,β-actin,Mouse,Monoclonal,,,,
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,"rabbit anti-GAPDH, rabbit anti-Histone 3, rabbit anti-Merlin, mouse anti-p53, mouse anti-Ki67, and rabbit anti-β-catenin, all from Cell Signaling",0.95,Accept,Experimental Usage,Merlin,Rabbit,Polyclonal,,,,
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,"mouse anti-NHE1 (clone 54), anti-Poly-ADP Ribose Polymerase (PARP), anti-cleaved PARP (Asp214) and anti-pSer807/811-Rb, all from Santa Cruz Biotechnology",0.9,Accept,Experimental Usage,NHE1,Mouse,Monoclonal,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"Antibodies recognizing ERRB3 Y1197, ERBB3, EPHA2 S897... were from Cell Signaling",0.9,Accept,Experimental Usage,ERBB3 Y1197,,,,,Human,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"Antibodies recognizing ERRB3 Y1197, ERBB3, EPHA2 S897... were from Cell Signaling",0.9,Accept,Experimental Usage,ERBB3,,,,,Human,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"Antibodies recognizing ERRB3 Y1197, ERBB3, EPHA2 S897... were from Cell Signaling",0.9,Accept,Experimental Usage,EPHA2 S897,,,,,Human,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"Antibodies recognizing... NDRG1 T346, Akt S473... were from Cell Signaling",0.9,Accept,Experimental Usage,NDRG1 T346,,,,,Human,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"Antibodies recognizing... NDRG1 T346, Akt S473, Akt T308... were from Cell Signaling",0.9,Accept,Experimental Usage,Akt S473,,,,,Human,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"Antibodies recognizing... Akt S473, Akt T308, Akt... were from Cell Signaling",0.9,Accept,Experimental Usage,Akt T308,,,,,Human,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"Antibodies recognizing... Akt T308, Akt, p70S6K T389... were from Cell Signaling",0.9,Accept,Experimental Usage,Akt,,,,,Human,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"Antibodies recognizing... Akt, p70S6K T389, p70S6K... were from Cell Signaling",0.9,Accept,Experimental Usage,p70S6K T389,,,,,Human,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"Antibodies recognizing... p70S6K T389, p70S6K, ribosomal S6 S240/244... were from Cell Signaling",0.9,Accept,Experimental Usage,p70S6K,,,,,Human,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"Antibodies recognizing... p70S6K, ribosomal S6 S240/244, S6... were from Cell Signaling",0.9,Accept,Experimental Usage,ribosomal S6 S240/244,,,,,Human,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"Antibodies recognizing... ribosomal S6 S240/244, S6, IGF1R Y1135/36/IR Y1150/51... were from Cell Signaling",0.9,Accept,Experimental Usage,S6,,,,,Human,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"Antibodies recognizing... S6, IGF1R Y1135/36/IR Y1150/51, IGF1R... were from Cell Signaling",0.9,Accept,Experimental Usage,IGF1R Y1135/36/IR Y1150/51,,,,,Human,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"Antibodies recognizing... IGF1R Y1135/36/IR Y1150/51, IGF1R, FOXO1/3a T24/T32... were from Cell Signaling",0.9,Accept,Experimental Usage,IGF1R,,,,,Human,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"Antibodies recognizing... IGF1R, FOXO1/3a T24/T32, and FOXO3 were from Cell Signaling",0.9,Accept,Experimental Usage,FOXO1/3a T24/T32,,,,,Human,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"Antibodies recognizing... FOXO1/3a T24/T32, and FOXO3 were from Cell Signaling",0.9,Accept,Experimental Usage,FOXO3,,,,,Human,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,Other antibodies included EPHA2 (Santa Cruz),0.9,Accept,Experimental Usage,EPHA2,,,,,Human,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,Other antibodies included... secreted form of NRG1 (R&D Systems),0.9,Accept,Experimental Usage,secreted form of NRG1,,,,,Human,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,Other antibodies included... NDRG1 (Abcam),0.9,Accept,Experimental Usage,NDRG1,,,,,Human,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,Other antibodies included... and GAPDH (EMD Millipore),0.9,Accept,Experimental Usage,GAPDH,,,,,Human,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,Anti-NF2/merlin polyclonal antibody has been previously described,0.9,Accept,Experimental Usage,NF2/merlin,,Polyclonal,,,Human,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"STING (13647S, Cell Signaling Technology)",0.9,Accept,Experimental Usage,STING,Unknown,Unknown,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"TBK1 (3504T, Cell Signaling Technology)",0.9,Accept,Experimental Usage,TBK1,Unknown,Unknown,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"p-TBK1 (s172) (5483T, Cell Signaling Technology)",0.9,Accept,Experimental Usage,p-TBK1,Unknown,Unknown,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"IRF3 (MA5-32348, Invitrogen, Thermo Fisher Scientific)",0.9,Accept,Experimental Usage,IRF3,Unknown,Unknown,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"p-IRF3 (4947S, Cell Signaling Technology)",0.9,Accept,Experimental Usage,p-IRF3,Unknown,Unknown,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"NF-κB (ab16502, Abcam)",0.9,Accept,Experimental Usage,NF-κB,Unknown,Unknown,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"p–NF-κB (3033S, Cell Signaling Technology)",0.9,Accept,Experimental Usage,p-NF-κB,Unknown,Unknown,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"PD-L1 (ab213480, Abcam, 66248-1-Ig, Proteintech)",0.9,Accept,Experimental Usage,PD-L1,Unknown,Unknown,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"GAPDH (SC-32233, Santa Cruz Biotechnology)",0.9,Accept,Experimental Usage,GAPDH,Unknown,Unknown,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"vinculin (4650S, Cell Signaling Technology)",0.9,Accept,Experimental Usage,vinculin,Unknown,Unknown,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"Foxp3 (ab215206, Abcam)",0.9,Accept,Experimental Usage,Foxp3,Unknown,Unknown,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"CTLA-4 (BE0164, Bio X Cell)",0.9,Accept,Experimental Usage,CTLA-4,Unknown,Monoclonal,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"CD20 (BS-0080R, Bioss)",0.9,Accept,Experimental Usage,CD20,Unknown,Unknown,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"CD3 (ab16669, Abcam)",0.9,Accept,Experimental Usage,CD3,Unknown,Unknown,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"CD4 (ab183685, Abcam)",0.9,Accept,Experimental Usage,CD4,Unknown,Unknown,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,CD8α (PA5-81344),0.85,Accept,Experimental Usage,CD8α,Unknown,Unknown,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"Iba1 (019-19741, Thermo Fisher Scientific)",0.9,Accept,Experimental Usage,Iba1,Unknown,Unknown,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"iNOS (ab15323, Abcam)",0.9,Accept,Experimental Usage,iNOS,Unknown,Unknown,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"mannose receptor (ab64693, Abcam)",0.9,Accept,Experimental Usage,mannose receptor,Unknown,Unknown,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"p-H3 (ser10) (9701s, Cell Signaling Technology)",0.9,Accept,Experimental Usage,p-H3,Unknown,Unknown,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"cleaved caspase 3 (9661S, Cell Signaling Technology)",0.9,Accept,Experimental Usage,cleaved caspase 3,Unknown,Unknown,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"cleaved PARP (9488S, Cell Signaling Technology)",0.9,Accept,Experimental Usage,cleaved PARP,Unknown,Unknown,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"anti–PD-1 (ab214421, Abcam; 66220-1-Ig, Proteintech) antibodies",0.9,Accept,Experimental Usage,PD-1,Unknown,Unknown,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"250 μg mouse monoclonal anti–PD-1 antibody (BE0146, Bio X Cell)",0.9,Accept,Experimental Usage,PD-1,Mouse,Monoclonal,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"100 μg mouse monoclonal anti–PD-L1 antibody (BE0146, Bio X Cell)",0.9,Accept,Experimental Usage,PD-L1,Mouse,Monoclonal,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"300 μg mouse monoclonal anti–CTLA-4 antibody (BE0164, Bio X Cell)",0.9,Accept,Experimental Usage,CTLA-4,Mouse,Monoclonal,,,,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,Anti-mCD3 (145–2C11) and anti-mIL6 receptor (15A7) antibodies were purchased from BioXcell.,0.95,Accept,Experimental Usage,CD3,Unknown,Monoclonal,,,Mouse,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,Anti-mCD3 (145–2C11) and anti-mIL6 receptor (15A7) antibodies were purchased from BioXcell.,0.95,Accept,Experimental Usage,IL6 receptor,Unknown,Monoclonal,,,Mouse,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,Anti-mTNFα antibody (R023) was purchased from Sino Biological,0.95,Accept,Experimental Usage,TNFα,Unknown,Unknown,,,Mouse,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,anti-mIL3 antibody (MP2–8F8) was purchased from BD Biosciences.,0.95,Accept,Experimental Usage,IL3,Unknown,Monoclonal,,,Mouse,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,"Primary antibody, anti-CD11b (1:8000 dilution; catalogue number ab133357, Abcam) was applied at 36 °C for 40 min.",0.95,Accept,Experimental Usage,CD11b,Unknown,Unknown,,,Mouse,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,Rabbit anti-NF1 antibody (A300-140A) was purchased from Bethyl Laboratories,0.95,Accept,Experimental Usage,NF1,Rabbit,Polyclonal,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,rabbit anti-phospho-ERK1/2 (p44/42 MAPK) (Thr202/Tyr204) antibody (#9101),0.95,Accept,Experimental Usage,phospho-ERK1/2,Rabbit,Polyclonal,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,anti-ERK1/2 (p44/42 MAPK) antibody (#9102),0.95,Accept,Experimental Usage,ERK1/2,Rabbit,Polyclonal,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,rabbit anti-GFP antibody (#2555) were purchased from Cell Signaling Technologies,0.95,Accept,Experimental Usage,GFP,Rabbit,Polyclonal,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,Goat anti-GFP antibody (600-101-215) was purchased from Rockland Immunochemicals,0.95,Accept,Experimental Usage,GFP,Unknown,Polyclonal,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,The mouse anti-βIII-tubulin antibody Tuj1 was obtained from R&D system,0.95,Accept,Experimental Usage,βIII-tubulin,Mouse,Monoclonal,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,mouse anti-NGFR (p75) antibody (AB-N07) was purchased from Advanced Targeting System,0.95,Accept,Experimental Usage,NGFR,Mouse,Monoclonal,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,rabbit anti-S100B antibody (Z0311) was purchased from DAKO,0.95,Accept,Experimental Usage,S100B,Rabbit,Polyclonal,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,"The anti-βActin (C-11, SC-1615HRP) HRP antibody was purchased from Santa Cruz Biotechnology",0.95,Accept,Experimental Usage,βActin,Mouse,Monoclonal,,,,HRP
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,mouse anti-HA antibody (26183) was purchased from Invitrogen,0.95,Accept,Experimental Usage,HA,Mouse,Monoclonal,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,Human Nuclear Antigen (HNA) recombinant rabbit Monoclonal Antibody (235-1 R) was purchased from ThermoFisher,0.95,Accept,Experimental Usage,Human Nuclear Antigen,Rabbit,Recombinant,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,"Western blotting and an antibody specific for NF1 (Abcam, Cambridge, United Kingdom; ab238142)",0.9,Accept,Experimental Usage,NF1,,,,,Human,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,"anti‐ Drosophila neurofibromin (mouse, ascites purified mAb21 and mAb30, 1 : 500 each)",0.9,Accept,Experimental Usage,Drosophila neurofibromin,Mouse,Monoclonal,,,Drosophila,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,"anti‐human neurofibromin (rabbit, Infixion r07E, San Diego, CA USA, 1 : 1000)",0.9,Accept,Experimental Usage,human neurofibromin,Rabbit,,,,Human,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,"anti‐phospho‐ERK (mouse, Sigma M8159, 1 : 2500)",0.9,Accept,Experimental Usage,phospho-ERK,Mouse,,,,Human,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,"total ERK (rabbit, CST 9102, Danvers, MA USA, 1 : 1000)",0.9,Accept,Experimental Usage,ERK,Rabbit,,,,Human,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,"anti‐β‐tubulin (mouse, Developmental Studies Hybridoma Bank E7, Iowa City, IA USA, 1 : 10 000)",0.9,Accept,Experimental Usage,β-tubulin,Mouse,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,"GAPDH (rabbit, Proteintech 10 494‐1‐AP, San Diego, CA USA, 1 : 15 000)",0.9,Accept,Experimental Usage,GAPDH,Rabbit,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,"anti‐PARP (rabbit, Cell Signaling 952, 1 : 1000)",0.9,Accept,Experimental Usage,PARP,Rabbit,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,"anti‐LC3B (rabbit, Cell Signaling 2775, 1 : 1000; CST Danvers, MA USA)",0.9,Accept,Experimental Usage,LC3B,Rabbit,,,,,
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,"Western blotting was performed with rabbit primary antibodies for p44/42 MAPK (ERK1/2), p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2), or phosphatidylinositol 3-kinase (PI3K), along with anti-rabbit conjugated secondary antibody, all purchased from New England Biolabs",0.95,Accept,Experimental Usage,p44/42 MAPK (ERK1/2),Rabbit,Unknown,,,,
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,"Western blotting was performed with rabbit primary antibodies for p44/42 MAPK (ERK1/2), p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2), or phosphatidylinositol 3-kinase (PI3K), along with anti-rabbit conjugated secondary antibody, all purchased from New England Biolabs",0.95,Accept,Experimental Usage,p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2),Rabbit,Unknown,,,,
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,"Western blotting was performed with rabbit primary antibodies for p44/42 MAPK (ERK1/2), p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2), or phosphatidylinositol 3-kinase (PI3K), along with anti-rabbit conjugated secondary antibody, all purchased from New England Biolabs",0.95,Accept,Experimental Usage,phosphatidylinositol 3-kinase (PI3K),Rabbit,Unknown,,,,
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,"Western blotting was performed with rabbit primary antibodies for p44/42 MAPK (ERK1/2), p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2), or phosphatidylinositol 3-kinase (PI3K), along with anti-rabbit conjugated secondary antibody, all purchased from New England Biolabs",0.9,Accept,Experimental Usage,rabbit IgG,,Secondary,,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,Primary ATRX antibody was from Sigma-Aldrich (HPA001906) and was used at 1:200 dilution,0.9,Accept,Experimental Usage,ATRX,Unknown,Unknown,,,Human,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,"Primary antibodies were incubated at 4 °C overnight: CD3 (Dako, A0452, 1:200)",0.9,Accept,Experimental Usage,CD3,Unknown,Unknown,,,Human,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,"CD8 (Leica NCL-L-CD8–4B11, 1:200)",0.9,Accept,Experimental Usage,CD8,Unknown,Monoclonal,,,Human,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,"GZMB (Leica, PA0291, ready to use)",0.9,Accept,Experimental Usage,GZMB,Unknown,Unknown,,,Human,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,"CD20 (Leica, NCL-L-CD20-L26, 1:200)",0.9,Accept,Experimental Usage,CD20,Unknown,Monoclonal,,,Human,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,"CD68 (Sigma, HPA048982, 1:2,000)",0.9,Accept,Experimental Usage,CD68,Unknown,Unknown,,,Human,
PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,,"S100 (1:400, Dako, Glostrun Denman, Carpinteria, CA) was visualized using fluorescent immunohistochemistry",0.85,Accept,Experimental Usage,S100,Unknown,Unknown,,,,
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,"The slides were incubated in their prospective antibodies for 30 min: indoleamine 2,3-dioxygenase rabbit monoclonal (1:100, Abcam, Cambridge, UK)",0.95,Accept,Experimental Usage,"indoleamine 2,3-dioxygenase",Rabbit,Monoclonal,,,,
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,"AHR antibody mouse monoclonal (1:50, Santa Cruz, Dallas, TX, USA)",0.95,Accept,Experimental Usage,AHR,Mouse,Monoclonal,,,,
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,"antibody-TDO2, rabbit/IgG polyclonal (1:100, Proteintech, Rosemont, IL, USA)",0.95,Accept,Experimental Usage,TDO2,Rabbit,Polyclonal,,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,"The antibodies used in the study included: Merlin (1:1000), pMerlin (1:500), HDAC1 (1:1000) and PDLIM2 (1:500) from Cell Signaling Technology",0.9,Accept,Experimental Usage,Merlin,Unknown,Unknown,,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,"The antibodies used in the study included: Merlin (1:1000), pMerlin (1:500), HDAC1 (1:1000) and PDLIM2 (1:500) from Cell Signaling Technology",0.9,Accept,Experimental Usage,phospho-Merlin,Unknown,Unknown,,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,"The antibodies used in the study included: Merlin (1:1000), pMerlin (1:500), HDAC1 (1:1000) and PDLIM2 (1:500) from Cell Signaling Technology",0.9,Accept,Experimental Usage,HDAC1,Unknown,Unknown,,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,"The antibodies used in the study included: Merlin (1:1000), pMerlin (1:500), HDAC1 (1:1000) and PDLIM2 (1:500) from Cell Signaling Technology",0.9,Accept,Experimental Usage,PDLIM2,Unknown,Unknown,,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,PDLIM2 (1:500) from Santa Cruz Biotechnology and GAPDH (1:50.000) from Millipore,0.9,Accept,Experimental Usage,PDLIM2,Unknown,Unknown,,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,PDLIM2 (1:500) from Santa Cruz Biotechnology and GAPDH (1:50.000) from Millipore,0.9,Accept,Experimental Usage,GAPDH,Unknown,Unknown,,,,
PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,"examined for EMA, vimentin, and Ki‐67 (as detected by MIB‐1 antibody) via immunohistochemical (IHC) staining. The primary antibodies were all obtained from Abcam.",0.85,Accept,Experimental Usage,EMA,Unknown,Unknown,,,,
PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,"examined for EMA, vimentin, and Ki‐67 (as detected by MIB‐1 antibody) via immunohistochemical (IHC) staining. The primary antibodies were all obtained from Abcam.",0.85,Accept,Experimental Usage,vimentin,Unknown,Unknown,,,,
PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,"examined for EMA, vimentin, and Ki‐67 (as detected by MIB‐1 antibody) via immunohistochemical (IHC) staining. The primary antibodies were all obtained from Abcam.",0.85,Accept,Experimental Usage,Ki-67,Unknown,Unknown,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,"CD31 (ab28364, 1:50, Abcam) and AXL (ab227871, 1:500, Abcam)",0.95,Accept,Experimental Usage,CD31,Unknown,Unknown,,,"Human, Mouse",Non-conjugated
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,"CD31 (ab28364, 1:50, Abcam) and AXL (ab227871, 1:500, Abcam)",0.95,Accept,Experimental Usage,AXL,Unknown,Unknown,,,"Human, Mouse",Non-conjugated
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,"pAXL (Cat#5724, 1:1000, Cell Signaling Technology), AXL (Cat#ab215205, 1:1000, Abcam)",0.95,Accept,Experimental Usage,pAXL,Unknown,Unknown,,,"Human, Mouse",Non-conjugated
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,"pAXL (Cat#5724, 1:1000, Cell Signaling Technology), AXL (Cat#ab215205, 1:1000, Abcam)",0.95,Accept,Experimental Usage,AXL,Unknown,Unknown,,,"Human, Mouse",Non-conjugated
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,"pAKT (Cat #9271, 1:1000, Cell Signaling Technology), pGSK-3β (Cat#9323, 1:1000, Cell Signaling Technology)",0.95,Accept,Experimental Usage,pAKT,Unknown,Unknown,,,"Human, Mouse",Non-conjugated
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,"pAKT (Cat #9271, 1:1000, Cell Signaling Technology), pGSK-3β (Cat#9323, 1:1000, Cell Signaling Technology)",0.95,Accept,Experimental Usage,pGSK-3β,Unknown,Unknown,,,"Human, Mouse",Non-conjugated
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,"pMEK1/2 (Cat#9121, 1:1000, Cell Signaling Technology), and GAPDH (#CST-5174, 1:1000, Cell Signaling Technology)",0.95,Accept,Experimental Usage,pMEK1/2,Unknown,Unknown,,,"Human, Mouse",Non-conjugated
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,"pMEK1/2 (Cat#9121, 1:1000, Cell Signaling Technology), and GAPDH (#CST-5174, 1:1000, Cell Signaling Technology)",0.95,Accept,Experimental Usage,GAPDH,Unknown,Unknown,,,"Human, Mouse",Non-conjugated
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,"anti-CalbindinD-28K (rabbit polyclonal, 1:2000 Swant CB-38a, Marly, Switzerland",0.9,Accept,Experimental Usage,CalbindinD-28K,Rabbit,Polyclonal,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,"mouse monoclonal 1:1000 Sigma-Aldrich (clone CB-955), Munich, Germany",0.9,Accept,Experimental Usage,CalbindinD-28K,Mouse,Monoclonal,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,"anti-Merlin (rabbit polyclonal antibody, A-19 (sc-331) and C-18 (sc-332), 1:50; Santa Cruz",0.9,Accept,Experimental Usage,Merlin,Rabbit,Polyclonal,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,"anti-Merlin (rabbit polyclonal antibody, A-19 (sc-331) and C-18 (sc-332), 1:50; Santa Cruz",0.9,Accept,Experimental Usage,Merlin,Rabbit,Polyclonal,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,"anti-Olig2 (mouse monoclonal antibody, 1:500; Millipore (AB9610), Darmstadt, Germany)",0.9,Accept,Experimental Usage,Olig2,Mouse,Monoclonal,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,"anti-MBP (mouse monoclonal antibody, 1:500; Chemikon (MAB384), Schwalbach, Germany)",0.9,Accept,Experimental Usage,MBP,Mouse,Monoclonal,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,"anti-Merlin (clone A-19 and C-18, 1:50, Santa Cruz Biotechnology, Heidelberg, Germany; or HPA003097, 1:100, Atlas Antibodies",0.9,Accept,Experimental Usage,Merlin,,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,"anti-GFP (A11122, 1:500, Thermo Fisher, Schwerte, Germany)",0.9,Accept,Experimental Usage,GFP,,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,"anti Ki67 (15580, 1:500, Abcam, Cambridge, UK)",0.9,Accept,Experimental Usage,Ki67,,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,"anti phospho-Histone H3 (pH3-Ser10, 06–570, 1:1000, Millipore, Darmstadt, Germany)",0.9,Accept,Experimental Usage,phospho-Histone H3,,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,"anti-NF2 clone C-18, 1:500, Santa Cruz, Heidelberg, Germany",0.9,Accept,Experimental Usage,NF2,,Monoclonal,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,"anti-phospho S518-Merlin 1:1000, and anti-cyclophilin B 1:4000, Abcam, Cambridge, UK",0.9,Accept,Experimental Usage,phospho S518-Merlin,,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,"anti-phospho S518-Merlin 1:1000, and anti-cyclophilin B 1:4000, Abcam, Cambridge, UK",0.9,Accept,Experimental Usage,cyclophilin B,,,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,"Tumor paraffin sections stained for MAF (Imgenex), pS6, pERK (Cell Signaling), and DEPTOR (Novus)",0.9,Accept,Experimental Usage,MAF,Unknown,Unknown,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,"Tumor paraffin sections stained for MAF (Imgenex), pS6, pERK (Cell Signaling), and DEPTOR (Novus)",0.9,Accept,Experimental Usage,pS6,Unknown,Unknown,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,"Tumor paraffin sections stained for MAF (Imgenex), pS6, pERK (Cell Signaling), and DEPTOR (Novus)",0.9,Accept,Experimental Usage,pERK,Unknown,Unknown,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,"Tumor paraffin sections stained for MAF (Imgenex), pS6, pERK (Cell Signaling), and DEPTOR (Novus)",0.9,Accept,Experimental Usage,DEPTOR,Unknown,Unknown,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,"Membranes were probed with antibodies for MAF (Imgenex), SOX9 (Santa Cruz), S100β (Dako)",0.9,Accept,Experimental Usage,SOX9,Unknown,Unknown,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,"Primary antibodies used were S100β (Dako), MBP (Chemicon), and BLBP (Millipore)",0.9,Accept,Experimental Usage,S100β,Unknown,Unknown,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,"Primary antibodies used were S100β (Dako), MBP (Chemicon), and BLBP (Millipore)",0.9,Accept,Experimental Usage,MBP,Unknown,Unknown,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,"Primary antibodies used were S100β (Dako), MBP (Chemicon), and BLBP (Millipore)",0.9,Accept,Experimental Usage,BLBP,Unknown,Unknown,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,"Membranes were probed with antibodies for MAF (Imgenex), SOX9 (Santa Cruz), S100β (Dako), MBP (Chemicon), BLBP (Millipore), DEPTOR (Novus), cleaved-caspase 3",0.9,Accept,Experimental Usage,cleaved-caspase 3,Unknown,Unknown,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,"p473AKT, AKT, and β-ACTIN (Cell Signaling) as a loading control",0.9,Accept,Experimental Usage,β-ACTIN,Unknown,Unknown,,,,
PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,Immunohistochemical analysis showed scattered S100 positivity in tumor cell nuclei,0.85,Accept,Experimental Usage,S100,Unknown,Unknown,,,,
PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,strong and diffuse CD34 positivity in the tumor cell cytoplasm,0.85,Accept,Experimental Usage,CD34,Unknown,Unknown,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,Antibodies were sourced as follows: RHAMM (Epitomics),0.85,Accept,Experimental Usage,RHAMM,Unknown,Unknown,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,TPX2 (Novus),0.85,Accept,Experimental Usage,TPX2,Unknown,Unknown,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,nestin (Covance),0.85,Accept,Experimental Usage,nestin,Unknown,Unknown,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,Tuj1 (Covance),0.85,Accept,Experimental Usage,Tuj1,Unknown,Unknown,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,β-actin (Sigma),0.85,Accept,Experimental Usage,β-actin,Unknown,Unknown,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,"AURKA, phospho (p)-AURKA (Thr288), p-histone H3 (Ser10), and caspase 9 (Cell Signalling)",0.85,Accept,Experimental Usage,AURKA,Unknown,Unknown,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,phospho (p)-AURKA (Thr288),0.85,Accept,Experimental Usage,phospho-AURKA (Thr288),Unknown,Unknown,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,p-histone H3 (Ser10),0.85,Accept,Experimental Usage,p-histone H3 (Ser10),Unknown,Unknown,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,caspase 9 (Cell Signalling),0.85,Accept,Experimental Usage,caspase 9,Unknown,Unknown,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,The p-RHAMM (Thr703) polyclonal antibody is characterized in [11],0.9,Accept,Experimental Usage,p-RHAMM (Thr703),Unknown,Polyclonal,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,"we used antibodies to PDGFRβ (rabbit; Abcam, ab32570), α-SMA (mouse; Sigma-Aldrich, clone 1A4, A2547)",0.9,Accept,Experimental Usage,PDGFRβ,Rabbit,Unknown,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,"α-SMA (mouse; Sigma-Aldrich, clone 1A4, A2547), IBA1 (rabbit; Wako Chemicals, 019-19741)",0.9,Accept,Experimental Usage,α-SMA,Mouse,Monoclonal,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,"IBA1 (rabbit; Wako Chemicals, 019-19741), CD3 (rat; Bio-Rad, MCA1477)",0.9,Accept,Experimental Usage,IBA1,Rabbit,Unknown,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,"CD3 (rat; Bio-Rad, MCA1477), GLUT1 (rabbit; Abcam, ab652)",0.9,Accept,Experimental Usage,CD3,Unknown,Unknown,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,"GLUT1 (rabbit; Abcam, ab652), cleaved caspase-3 (rabbit; Cell Signaling Technology, #9661)",0.9,Accept,Experimental Usage,GLUT1,Rabbit,Unknown,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,"cleaved caspase-3 (rabbit; Cell Signaling Technology, #9661), BrdU (rat; Abcam, ab6326)",0.9,Accept,Experimental Usage,cleaved caspase-3,Rabbit,Unknown,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,"BrdU (rat; Abcam, ab6326), VEGFA (rabbit; ABclonal, A0280)",0.9,Accept,Experimental Usage,BrdU,Unknown,Unknown,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,"VEGFA (rabbit; ABclonal, A0280), ALDH1A1 (rabbit; Proteintech, 15910-1-AP)",0.9,Accept,Experimental Usage,VEGFA,Rabbit,Unknown,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,"ALDH1A1 (rabbit; Proteintech, 15910-1-AP), ZEB1 (rabbit; ABclonal, A5600)",0.9,Accept,Experimental Usage,ALDH1A1,Rabbit,Unknown,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,"ZEB1 (rabbit; ABclonal, A5600), IGFBP2 (rabbit; Cell Signaling Technology, #3922)",0.9,Accept,Experimental Usage,ZEB1,Rabbit,Unknown,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,"IGFBP2 (rabbit; Cell Signaling Technology, #3922), Nestin (mouse; Millipore, MAB353)",0.9,Accept,Experimental Usage,IGFBP2,Rabbit,Unknown,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,"Nestin (mouse; Millipore, MAB353), EYA4 (rabbit; Thermo Fisher Scientific, PA5-52113)",0.9,Accept,Experimental Usage,Nestin,Mouse,Monoclonal,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,"EYA4 (rabbit; Thermo Fisher Scientific, PA5-52113), SOX2 (goat; Santa Cruz Biotechnology, sc-17320)",0.9,Accept,Experimental Usage,EYA4,Rabbit,Unknown,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,"SOX2 (goat; Santa Cruz Biotechnology, sc-17320), and YAP/TAZ (rabbit; Cell Signaling Technology, #8418)",0.9,Accept,Experimental Usage,SOX2,Unknown,Unknown,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,"YAP/TAZ (rabbit; Cell Signaling Technology, #8418). Secondary antibodies conjugated to Alexa Fluor 488",0.9,Accept,Experimental Usage,YAP/TAZ,Rabbit,Unknown,,,,
PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,,"GAP43 (rabbit, 1:1000, Abcam)",0.9,Accept,Experimental Usage,GAP43,Rabbit,Unknown,,,,
PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,,"S100β (rabbit, 1:5000, DAKO)",0.9,Accept,Experimental Usage,S100β,Rabbit,Unknown,,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,"Blots were probed overnight at 4 °C with either the neurofibromin antibody (Cell Signaling Technologies Cat. #: 14623 S; Danvers, MA, USA)",0.9,Accept,Experimental Usage,neurofibromin,Unknown,Unknown,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,Schwann cells were isolated from contaminating fibroblasts via p75 NGFR antibody-mediated magnetic cell selection,0.9,Accept,Experimental Usage,p75 NGFR,Unknown,Unknown,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,"using mouse anti-Ki67 (1:2,000, BD Biosciences 556003 lot 8239549)",0.9,Accept,Experimental Usage,Ki67,Mouse,Monoclonal,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,"rabbit anti-CD8 (1:500, Cell Signaling Technology 98941T lot 5)",0.9,Accept,Experimental Usage,CD8,Rabbit,Monoclonal,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,"goat anti-PDGFRα (1:2,000, R&D Systems AF1062 RRID: AB_2236897)",0.9,Accept,Experimental Usage,PDGFRα,Unknown,Polyclonal,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,"rabbit anti-S100β (1:2,000, Abcam ab52642 lot GR3215095-1)",0.9,Accept,Experimental Usage,S100β,Rabbit,Unknown,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,"rabbit anti-IBA1 (1:1,000, Abcam ab178846 lot GR3185035-4)",0.9,Accept,Experimental Usage,IBA1,Rabbit,Unknown,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,"mouse anti-BRN3A (1:200, Santa Cruz Biotechnology sc-8429 lot H1718)",0.9,Accept,Experimental Usage,BRN3A,Mouse,Monoclonal,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,"rabbit anti-NLGN3, 1:500, Novus NBP1-90080 lot B118108",0.9,Accept,Experimental Usage,NLGN3,Rabbit,Unknown,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,"rabbit anti-β-actin, 1:10,000, Cell Signaling 4970 lot 15",0.9,Accept,Experimental Usage,β-actin,Rabbit,Unknown,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,"rabbit anti-ADAM10, 1:250, Abcam ab124695 lot GR3244660-5",0.9,Accept,Experimental Usage,ADAM10,Rabbit,Unknown,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,"rabbit anti-cleaved caspase-3, 1:500, R&D Systems MAB835 lot KHK051810A",0.9,Accept,Experimental Usage,cleaved caspase-3,Rabbit,Monoclonal,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,"rabbit anti-caspase-3, 1:1,000, Cell Signaling 9662 lot 19",0.9,Accept,Experimental Usage,caspase-3,Rabbit,Unknown,,,,
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,"Additionally, axons were identified by immunolabeling with tau 1 antibodies (not shown)",0.85,Accept,Experimental Usage,tau 1,,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,"Primary antibodies for B-Actin(1:1000, Cat #8457S, Cell Signaling Technologies)",0.9,Accept,Experimental Usage,B-Actin,Unknown,Unknown,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,"Vinculin(1:30000, Cat #V9264, Sigma Aldrich)",0.9,Accept,Experimental Usage,Vinculin,Unknown,Unknown,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,"PTCH1(1:500,Cat#MAB41051, R&D systems)",0.9,Accept,Experimental Usage,PTCH1,Unknown,Unknown,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,"APC(1:500, Cat #15270, Abcam)",0.9,Accept,Experimental Usage,APC,Unknown,Unknown,,,,
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,"cells were fixed with 4% paraformaldehyde and stained with antibodies against Tuj-1 (neuron), O4 (oligodendrocyte) and GFAP (astrocyte)",0.85,Accept,Experimental Usage,Tuj-1,Unknown,Unknown,,,,
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,"cells were fixed with 4% paraformaldehyde and stained with antibodies against Tuj-1 (neuron), O4 (oligodendrocyte) and GFAP (astrocyte)",0.85,Accept,Experimental Usage,O4,Unknown,Unknown,,,,
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,"cells were fixed with 4% paraformaldehyde and stained with antibodies against Tuj-1 (neuron), O4 (oligodendrocyte) and GFAP (astrocyte)",0.85,Accept,Experimental Usage,GFAP,Unknown,Unknown,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,"Sections were then incubated overnight at 4°C in a humidified chamber with primary antibody (β-catenin, 1:100, Cell Signaling)",0.9,Accept,Experimental Usage,β-catenin,Unknown,Unknown,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,"The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling)",0.9,Accept,Experimental Usage,activated β-catenin,Unknown,Unknown,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,"The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling)",0.9,Accept,Experimental Usage,β-catenin,Unknown,Unknown,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,"The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling)",0.9,Accept,Experimental Usage,GSK3B,Unknown,Unknown,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,"The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling)",0.9,Accept,Experimental Usage,AXIN1,Unknown,Unknown,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,"The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling)",0.9,Accept,Experimental Usage,GAPDH,Unknown,Unknown,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,"Immunohistochemistry for CCND1 (SP4) monoclonal antibody (Neomarkers, Thermo Scientific, 1:50) and β-catenin (6B3) monoclonal antibody (Cell Signaling; 1:200)",0.9,Accept,Experimental Usage,CCND1,Unknown,Monoclonal,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,"Immunohistochemistry for CCND1 (SP4) monoclonal antibody (Neomarkers, Thermo Scientific, 1:50) and β-catenin (6B3) monoclonal antibody (Cell Signaling; 1:200)",0.9,Accept,Experimental Usage,β-catenin,Unknown,Monoclonal,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,"primary goat polyclonal anti‐HK2 (sc‐6521, Santa Cruz) and rabbit monoclonal anti‐MPP2",0.95,Accept,Experimental Usage,HK2,Unknown,Polyclonal,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,"rabbit monoclonal anti‐MPP2 (ab92536, Abcam) antibodies",0.95,Accept,Experimental Usage,MPP2,Rabbit,Monoclonal,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,"anti‐GAPDH (#2118, Cell Signaling), ATP5A (ab14748, Abcam)",0.95,Accept,Experimental Usage,GAPDH,Unknown,Unknown,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,"ATP5A (ab14748, Abcam), anti‐UQCRC2 (ab14745, Abcam)",0.95,Accept,Experimental Usage,ATP5A,Unknown,Unknown,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,"anti‐UQCRC2 (ab14745, Abcam), rabbit monoclonal anti‐MMP2 (ab92536, Abcam)",0.95,Accept,Experimental Usage,UQCRC2,Unknown,Unknown,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,"rabbit monoclonal anti‐MMP9 (ab137867, Abcam) rabbit polyclonal, and TOM20",0.95,Accept,Experimental Usage,MMP9,Rabbit,Monoclonal,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,"TOM20 (sc‐11415, Santa Cruz) antibodies",0.95,Accept,Experimental Usage,TOM20,Unknown,Unknown,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,"Primary antibodies (rabbit monoclonal anti‐HK2, H.738.7, Thermo Scientific; mouse monoclonal anti‐TOM20",0.95,Accept,Experimental Usage,HK2,Rabbit,Monoclonal,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,"mouse monoclonal anti‐TOM20, sc‐17764, Santa Cruz) were diluted 1:150",0.95,Accept,Experimental Usage,TOM20,Mouse,Monoclonal,,,,
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,"incubated overnight with the primary anti-neurofibromin antibody (abcam, ab17963, 1/1000)",0.95,Accept,Experimental Usage,neurofibromin,,Unknown,,,,
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,"Anti-beta-Actin antibody (Santa Cruz Biotechnologies, sc4778, 1/10,000) was used to verify equal protein loading",0.9,Accept,Experimental Usage,beta-Actin,,Unknown,,,,
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,"anti-vinculin (abcam, ab129002, 1/1000) was used to verify equal protein loading",0.9,Accept,Experimental Usage,vinculin,,Unknown,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,"neurofibromin/NF1 (sc-67, sc-376886, Santa Cruz Biotechnology and ab238142, Abcam)",0.95,Accept,Experimental Usage,neurofibromin/NF1,Unknown,Unknown,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,"neurofibromin/NF1 (sc-67, sc-376886, Santa Cruz Biotechnology and ab238142, Abcam)",0.95,Accept,Experimental Usage,neurofibromin/NF1,Unknown,Unknown,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,"neurofibromin/NF1 (sc-67, sc-376886, Santa Cruz Biotechnology and ab238142, Abcam)",0.95,Accept,Experimental Usage,neurofibromin/NF1,Unknown,Unknown,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,"Flag (F7425, MilliporeSigma)",0.95,Accept,Experimental Usage,Flag,Unknown,Unknown,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,"GFP (ab1218, Abcam, Western blotting and Invitrogen, IP)",0.95,Accept,Experimental Usage,GFP,Unknown,Unknown,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,"FBXW11/bTrCP2 (GTX33193, GeneTex and PA5-109715, Invitrogen, Thermo Fisher Scientific)",0.95,Accept,Experimental Usage,FBXW11/bTrCP2,Unknown,Unknown,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,"ERK1/2 (9102, Cell Signaling Technology)",0.95,Accept,Experimental Usage,ERK1/2,Unknown,Unknown,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,"anti-pERK Thr202/Tyr204 (4377, Cell Signaling Technology)",0.95,Accept,Experimental Usage,pERK Thr202/Tyr204,Unknown,Unknown,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,mouse monoclonal anti-human TRAP1 (sc-73604),0.9,Accept,Experimental Usage,TRAP1,Mouse,Monoclonal,,,Human,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,mouse monoclonal anti ATP50/OSCP (ab110276) antibodies,0.9,Accept,Experimental Usage,ATP50/OSCP,Mouse,Monoclonal,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,mouse monoclonal anti-ATPB (ab14730),0.9,Accept,Experimental Usage,ATPB,Mouse,Monoclonal,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,anti SDHA (sc-166947),0.9,Accept,Experimental Usage,SDHA,Mouse,Monoclonal,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,mouse monoclonal anti-Cyclophilin (ab110324) antibodies,0.9,Accept,Experimental Usage,Cyclophilin,Mouse,Monoclonal,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,"glial fibrillary acidic protein (GFAP, DAKO, polyclonal, 1:3,000 dilution, no antigen retrieval)",0.9,Accept,Experimental Usage,GFAP,Unknown,Polyclonal,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,"OLIG2 (Immuno Bio Labs, polyclonal, 1:200 dilution, ER1 antigen retrieval)",0.9,Accept,Experimental Usage,OLIG2,Unknown,Polyclonal,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,"SOX10 (Cell Marque, clone EP268, dilution 1:250, ER2 antigen retrieval)",0.9,Accept,Experimental Usage,SOX10,Unknown,Monoclonal,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,"synaptophysin (Cell Marque, polyclonal, 1:100 dilution, ER2 antigen retrieval)",0.9,Accept,Experimental Usage,synaptophysin,Unknown,Polyclonal,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,"p16 (MTM Labs, clone E6H4, undiluted, ER1 antigen retrieval)",0.9,Accept,Experimental Usage,p16,Unknown,Monoclonal,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,"ATRX (Sigma, polyclonal, 1:100 dilution)",0.9,Accept,Experimental Usage,ATRX,Unknown,Polyclonal,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,"p53 (Biocare, clone DO-7, 1:100 dilution, ER2 antigen retrieval)",0.9,Accept,Experimental Usage,p53,Unknown,Monoclonal,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,"histone H3 K27M mutant protein (RevMAb Biosciences, clone RM192, 1:600 dilution)",0.9,Accept,Experimental Usage,histone H3 K27M mutant protein,Unknown,Monoclonal,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,"histone H3 lysine 27 trimethylation (Cell Signaling, cat #9733, clone C36B11, 1:50 dilution, ER2 antigen retrieval)",0.9,Accept,Experimental Usage,histone H3 lysine 27 trimethylation,Unknown,Monoclonal,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,"Ki-67 (Dako, clone Mib1, 1:50 dilution, ER2 antigen retrieval)",0.9,Accept,Experimental Usage,Ki-67,Unknown,Monoclonal,,,,
PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,Blocking antibody (anti-CD16/CD32) was added to the cell suspensions and incubated 15 min,0.9,Accept,Experimental Usage,CD16/CD32,Unknown,Unknown,,,,
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,"mouse monoclonal (CA-4001) matrix metalloproteinase (MMP)2...dilution 1 : 1000; incubation overnight at 4 °C, Abcam",0.95,Accept,Experimental Usage,MMP2,Mouse,Monoclonal,,,,
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,"rabbit monoclonal (EP1254) MMP9 (dilution 1 : 1000; incubation overnight at 4 °C, Abcam",0.95,Accept,Experimental Usage,MMP9,Rabbit,Monoclonal,,,,
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,"MMP3 (dilution 1 : 50; incubation overnight at 4 °C, Santa Cruz Biotechnology, Inc.)",0.85,Accept,Experimental Usage,MMP3,,,,,,
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,GAPDH mouse mAb (6C5) (dilution 1 : 5000; incubation 1 h at room temperature; Advanced Immunochemical Inc.),0.95,Accept,Experimental Usage,GAPDH,Mouse,Monoclonal,,,,
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,"Tumors were stained first with CD45-Vioblue direct antibody conjugate (clone REA747, Miltenyi Biotec) for 30 min at 4 °C.",0.95,Accept,Experimental Usage,CD45,Unknown,Monoclonal,,,Human,Vioblue
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,"CD45 negative cells were stained with calcein AM (Life Technologies) for viability and CD24-APC (human antibody, clone REA832, Miltenyi Biotec)",0.95,Accept,Experimental Usage,CD24,Unknown,Monoclonal,,,Human,APC
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,"CD24-APC (human antibody, clone REA832, Miltenyi Biotec) and CD44-VioBlue (human antibody, clone REA690, Miltenyi Biotec)",0.95,Accept,Experimental Usage,CD44,Unknown,Monoclonal,,,Human,VioBlue
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,"HLA-B (anti-HLA Class I ABC antibody, ab225636, Abcam, Cambridge, UK) for MHC I",0.95,Accept,Experimental Usage,HLA Class I ABC,Unknown,Unknown,,,Human,Non-conjugated
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,"DPB1 (anti-MHC Class II antibody, ab55152, Abcam, Cambridge, UK) for MHC II",0.95,Accept,Experimental Usage,MHC Class II,Unknown,Unknown,,,Human,Non-conjugated
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,"labeled with primary antibodies including SOX10 to mark schwannoma cells (API 3099, Biocare; labeling validated in schwannoma and melanoma)",0.9,Accept,Experimental Usage,SOX10,,,,,Human,Non-conjugated
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,"Pericentrin (PA5-54109, Thermo Fisher Scientific; labeling validated by Pericentrin knockdown) and γTubulin (T5192, Sigma; labeling validated in human and chicken cells) to mark centrosomes",0.9,Accept,Experimental Usage,Pericentrin,,,,,Human,Non-conjugated
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,"Pericentrin (PA5-54109, Thermo Fisher Scientific; labeling validated by Pericentrin knockdown) and γTubulin (T5192, Sigma; labeling validated in human and chicken cells) to mark centrosomes",0.9,Accept,Experimental Usage,γTubulin,,,,,Human,Non-conjugated
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,"and Acetylated Tubulin to mark cilia (T6793, Sigma; labeling validated in vertebrate and invertebrate organisms)",0.9,Accept,Experimental Usage,Acetylated Tubulin,,,,,Human,Non-conjugated
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,"slides were subjected to antigen retrieval and labeled with CD3 (A0452, Agilent Technologies, Santa Clara, CA; labeling validated by over-expression)",0.9,Accept,Experimental Usage,CD3,,,,,Human,Non-conjugated
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,"or CD68 (M0814, Agilent Technologies; labeling validated using human B-cell lymphoma) primary antibodies",0.9,Accept,Experimental Usage,CD68,,,,,Human,Non-conjugated
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,"...incubated for 30 min in ice and in the dark with the following mouse anti-human monoclonal antibodies directly conjugated with fluorochromes: CD13/FITC (22A5, Caltag Medsystems, UK)...",0.9,Accept,Experimental Usage,CD13,Mouse,Monoclonal,,,Human,FITC
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,"...mouse anti-human monoclonal antibodies directly conjugated with fluorochromes: CD13/FITC (22A5, Caltag Medsystems, UK), CD14/PE (M5E2, BD Biosciences, CA, USA)...",0.9,Accept,Experimental Usage,CD14,Mouse,Monoclonal,,,Human,PE
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,"...CD14/PE (M5E2, BD Biosciences, CA, USA), CD34/FITC (581, BD Biosciences), CD45/ALexa405 (HI30, Caltag Medsystems)...",0.9,Accept,Experimental Usage,CD34,Mouse,Monoclonal,,,Human,FITC
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,"...CD34/FITC (581, BD Biosciences), CD45/ALexa405 (HI30, Caltag Medsystems), CD90/PECy5 (5E10, BioLegend, CA, USA)...",0.9,Accept,Experimental Usage,CD45,Mouse,Monoclonal,,,Human,Alexa405
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,"...CD45/ALexa405 (HI30, Caltag Medsystems), CD90/PECy5 (5E10, BioLegend, CA, USA), CD105/APC (45A5A3, BioLegend)...",0.9,Accept,Experimental Usage,CD90,Mouse,Monoclonal,,,Human,PECy5
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,"...CD90/PECy5 (5E10, BioLegend, CA, USA), CD105/APC (45A5A3, BioLegend), CD146/PE (P1H12, BD Biosciences)...",0.9,Accept,Experimental Usage,CD105,Mouse,Monoclonal,,,Human,APC
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,"...CD105/APC (45A5A3, BioLegend), CD146/PE (P1H12, BD Biosciences), CD271/APC (C401457, BD Biosciences)...",0.9,Accept,Experimental Usage,CD146,Mouse,Monoclonal,,,Human,PE
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,"...CD146/PE (P1H12, BD Biosciences), CD271/APC (C401457, BD Biosciences). Unstained cells were used as controls...",0.9,Accept,Experimental Usage,CD271,Mouse,Monoclonal,,,Human,APC
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,"...Expression of Ki-67 was evaluated immunohistochemically using mouse monoclonal antibody anti-Ki-67 (1:80; M7240; Dako Corporation, CA, USA)...",0.9,Accept,Experimental Usage,Ki-67,Mouse,Monoclonal,,,Human,Non-conjugated
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,"Pluripotency of hiPSCs was confirmed through immunocytochemistry for pluripotency markers (OCT3/4, NANOG, TRA-1-60 and SSEA-4)",0.9,Accept,Experimental Usage,OCT3/4,Unknown,Unknown,,,Human,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,"Pluripotency of hiPSCs was confirmed through immunocytochemistry for pluripotency markers (OCT3/4, NANOG, TRA-1-60 and SSEA-4)",0.9,Accept,Experimental Usage,NANOG,Unknown,Unknown,,,Human,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,"Pluripotency of hiPSCs was confirmed through immunocytochemistry for pluripotency markers (OCT3/4, NANOG, TRA-1-60 and SSEA-4)",0.9,Accept,Experimental Usage,TRA-1-60,Unknown,Unknown,,,Human,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,"Pluripotency of hiPSCs was confirmed through immunocytochemistry for pluripotency markers (OCT3/4, NANOG, TRA-1-60 and SSEA-4)",0.9,Accept,Experimental Usage,SSEA-4,Unknown,Unknown,,,Human,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,Cells were next stained with anti-IBA1 antibody (Table S1) in TBS containing 5% donkey serum overnight,0.9,Accept,Experimental Usage,IBA1,Unknown,Unknown,,,Human,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,incubated at 4 °C overnight in primary antibody; MKK3 (Cell Signaling #5674),0.9,Accept,Experimental Usage,MKK3,Unknown,Unknown,,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,p38 (Cell Signaling #9219),0.9,Accept,Experimental Usage,p38,Unknown,Unknown,,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,phospho-p38 (Cell Signaling # 4511),0.9,Accept,Experimental Usage,phospho-p38,Unknown,Unknown,,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,phospho-ERK1/2 (Cell Signaling #9101),0.9,Accept,Experimental Usage,phospho-ERK1/2,Unknown,Unknown,,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,β-Actin (Cell Signaling #3700),0.9,Accept,Experimental Usage,β-Actin,Unknown,Unknown,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,"we used antibodies to TAZ (Rabbit; Proteintech 23306-1), YAP (Rabbit; Cell Signaling Technology, #4912)",0.9,Accept,Experimental Usage,TAZ,Rabbit,Unknown,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,"YAP (Rabbit; Cell Signaling Technology, #4912), TAZ/YAP (Rabbit; Cell Signaling Technology, #8418)",0.9,Accept,Experimental Usage,YAP,Rabbit,Unknown,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,"TAZ/YAP (Rabbit; Cell Signaling Technology, #8418), Sox10 (Goat, Santa Cruz Biotechnology, sc-17342",0.9,Accept,Experimental Usage,TAZ/YAP,Rabbit,Unknown,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,"Sox10 (Goat, Santa Cruz Biotechnology, sc-17342; Rabbit, Abcam ab180862), Krox20 (Rabbit; Covance, PRB-236P)",0.9,Accept,Experimental Usage,Sox10,Unknown,Unknown,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,"Sox10 (Goat, Santa Cruz Biotechnology, sc-17342; Rabbit, Abcam ab180862), Krox20 (Rabbit; Covance, PRB-236P)",0.9,Accept,Experimental Usage,Sox10,Rabbit,Unknown,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,"Krox20 (Rabbit; Covance, PRB-236P), MBP (Goat; Santa Cruz Biotechnology, sc-13914)",0.9,Accept,Experimental Usage,Krox20,Rabbit,Unknown,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,"Ki67 (Rabbit; Thermo Fisher Scientific, RM-9106), BrdU (Rat; Abcam, ab6326)",0.9,Accept,Experimental Usage,Ki67,Rabbit,Unknown,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,"BrdU (Rat; Abcam, ab6326), α-SMA (Mouse; Sigma, clone 1A4, A2547)",0.9,Accept,Experimental Usage,BrdU,Unknown,Unknown,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,"TEAD1 (Mouse, Santa Cruz Biotechnology sc-393976), neurofibromin (Rabbit, Santa Cruz Biotechnology sc-67)",0.9,Accept,Experimental Usage,TEAD1,Mouse,Unknown,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,"neurofibromin (Rabbit, Santa Cruz Biotechnology sc-67), P53 (Rabbit, Cell Signaling Technology, #9282)",0.9,Accept,Experimental Usage,neurofibromin,Rabbit,Unknown,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,"The antibodies used were as follows: TEAD1 (Mouse, BD Biosciences, 610922), H3K4me1 (Rabbit, Abcam, 8895)",0.9,Accept,Experimental Usage,TEAD1,Mouse,Unknown,,,,
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,"anti-neurofibromin (#A300; Bethyl Laboratories, Montgomery, TX, USA)",0.9,Accept,Experimental Usage,neurofibromin,Unknown,Unknown,,,,Non-conjugated
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,"anti-phospho-Akt XP (#4060), anti-Akt (#2938S), anti-phospho-Erk XP (#4370), anti-Erk (#4695S; Cell Signaling, Danvers, MA, USA)",0.9,Accept,Experimental Usage,phospho-Akt,Unknown,Unknown,,,,Non-conjugated
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,"anti-phospho-Akt XP (#4060), anti-Akt (#2938S), anti-phospho-Erk XP (#4370), anti-Erk (#4695S; Cell Signaling, Danvers, MA, USA)",0.9,Accept,Experimental Usage,Akt,Unknown,Unknown,,,,Non-conjugated
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,"anti-phospho-Akt XP (#4060), anti-Akt (#2938S), anti-phospho-Erk XP (#4370), anti-Erk (#4695S; Cell Signaling, Danvers, MA, USA)",0.9,Accept,Experimental Usage,phospho-Erk,Unknown,Unknown,,,,Non-conjugated
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,"anti-phospho-Akt XP (#4060), anti-Akt (#2938S), anti-phospho-Erk XP (#4370), anti-Erk (#4695S; Cell Signaling, Danvers, MA, USA)",0.9,Accept,Experimental Usage,Erk,Unknown,Unknown,,,,Non-conjugated
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,"anti-phospho-endothelial nitric oxide synthase (eNOS) (612392) and FITC-anti-CD31 (BD Laboratories, San Jose, CA, USA)",0.9,Accept,Experimental Usage,CD31,Unknown,Unknown,,,,FITC
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,"and anti-GAPDH (Novus, Littleton, CO, USA)",0.85,Accept,Experimental Usage,GAPDH,Unknown,Unknown,,,,Non-conjugated
PMID:34646065,10.1155/2021/9386823,Survival and ,,immunohistochemical S100 B data from a pathology service...An S100 B immunonegative tumor phenotype was associated with a significantly worse outcome,0.85,Accept,Experimental Usage,S100 B,,,,,,
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,"goat monoclonal Iba-1 antibody targeting microglia (1:300; Abcam, Cambridge, UK)",0.95,Accept,Experimental Usage,Iba-1,Unknown,Monoclonal,,,Mouse,Non-conjugated
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,"chicken polyclonal GFP antibody targeting eYFP (1:250; Abcam, Cambridge, UK)",0.9,Accept,Experimental Usage,GFP,Unknown,Polyclonal,,,Mouse,Non-conjugated
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,mouse anti-NeuN targeting neurons (1:00; Synaptic Systems),0.9,Accept,Experimental Usage,NeuN,Mouse,Unknown,,,Mouse,Non-conjugated
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,"donkey anti-goat IgG conjugated with Cy5 or Alexa488 fluorophores (both 1:200; Dianova, Hamburg, Germany)",0.85,Accept,Experimental Usage,goat IgG,Unknown,Secondary,,,,Cy5
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,"donkey anti-goat IgG conjugated with Cy5 or Alexa488 fluorophores (both 1:200; Dianova, Hamburg, Germany)",0.85,Accept,Experimental Usage,goat IgG,Unknown,Secondary,,,,Alexa488
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,donkey anti-chicken IgY conjugated with Alexa488 or Cy5 (both 1:200; Dianova),0.85,Accept,Experimental Usage,chicken IgY,Unknown,Secondary,,,,Alexa488
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,donkey anti-chicken IgY conjugated with Alexa488 or Cy5 (both 1:200; Dianova),0.85,Accept,Experimental Usage,chicken IgY,Unknown,Secondary,,,,Cy5
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,NeuN with donkey anti-mouse IgG (H + L) conjugated with Cy3 (1:200; Dianova),0.85,Accept,Experimental Usage,mouse IgG,Unknown,Secondary,,,,Cy3
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,"incubated with anti-mouse CD11b antibodies coupled to magnetic beads (Miltenyi Biotech, Bergisch Gladbach, Germany)",0.9,Accept,Experimental Usage,CD11b,Unknown,Unknown,,,Mouse,magnetic beads
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,The following antibodies were purchased from Cell signaling Technologies: pERK (Catalogue # 4370),0.95,Accept,Experimental Usage,pERK,,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,total ERK (Catalogue # 9102),0.95,Accept,Experimental Usage,ERK,,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,pAKT (Catalogue # 4060),0.95,Accept,Experimental Usage,pAKT,,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,total AKT (Catalogue # 4691),0.95,Accept,Experimental Usage,AKT,,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,Ubiquitin (Catalogue # 4289),0.95,Accept,Experimental Usage,Ubiquitin,,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,MYC (Catalogue # 18583),0.95,Accept,Experimental Usage,MYC,,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,pCHEK1 S296 (Catalogue # 90178),0.95,Accept,Experimental Usage,pCHEK1 S296,,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,BMI1 (Catalogue # 5856),0.95,Accept,Experimental Usage,BMI1,,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,H3K27Ac (Catalogue # 8173),0.95,Accept,Experimental Usage,H3K27Ac,,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,total H3 (Catalogue # 14269),0.95,Accept,Experimental Usage,H3,,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,CDK9 (Catalogue # 2316),0.95,Accept,Experimental Usage,CDK9,,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,Vinculin (Catalogue # 4650),0.95,Accept,Experimental Usage,Vinculin,,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,CPNase (Catalogue # 5664),0.95,Accept,Experimental Usage,CPNase,,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,MAG (Catalogue # 9043),0.95,Accept,Experimental Usage,MAG,,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,Beta-Actin (Catalogue # NB600-501) was purchased from Novus,0.95,Accept,Experimental Usage,Beta-Actin,,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,pS2 RNApol II (Catalogue # 04-1571-1) from EMD Millipore,0.95,Accept,Experimental Usage,pS2 RNApol II,,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,SOX2 (Catalogue # MAB2018) from R&D systems,0.95,Accept,Experimental Usage,SOX2,,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,NG2 (Catalogue # PA5-17199) from Invitrogen,0.95,Accept,Experimental Usage,NG2,,,,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,"Antibodies used were: monoclonal anti-EGFR (1:250; Capralogics, Hardwick, MA)",0.9,Accept,Experimental Usage,EGFR,Unknown,Monoclonal,,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,"polyclonal anti-ErbB2 (1:250; Santa Cruz Biotechnology, Santa Cruz, CA)",0.9,Accept,Experimental Usage,ErbB2,Unknown,Polyclonal,,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,polyclonal anti-ErbB3 (1:250; Santa Cruz),0.9,Accept,Experimental Usage,ErbB3,Unknown,Polyclonal,,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,"polyclonal anti-merlin (1:250, Santa Cruz)",0.9,Accept,Experimental Usage,merlin,Unknown,Polyclonal,,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,"monoclonal anti-actin (BD Biosciences, San Jose, CA)",0.9,Accept,Experimental Usage,actin,Unknown,Monoclonal,,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,"Rabbit polyclonal anti-merlin (1:100; Santa Cruz Biotechnology, Santa Cruz, CA)",0.95,Accept,Experimental Usage,merlin,Rabbit,Polyclonal,,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,"cells were labeled with MPM-2 antibody (Upstate Biotechnology, Lake Placid, NY)",0.85,Accept,Experimental Usage,MPM-2,Unknown,Unknown,,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,Detection of Ras was done by immunoblotting using the supplied pan-Ras antibody,0.85,Accept,Experimental Usage,Ras,Unknown,Unknown,,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,"Membranes were blotted with antibodies specific for Cyclin D1, ERK, phospho-ERK, B-Raf, and Ku-70 (Santa Cruz Biotechnology)",0.85,Accept,Experimental Usage,Cyclin D1,Unknown,Unknown,,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,"Membranes were blotted with antibodies specific for Cyclin D1, ERK, phospho-ERK, B-Raf, and Ku-70 (Santa Cruz Biotechnology)",0.85,Accept,Experimental Usage,ERK,Unknown,Unknown,,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,"Membranes were blotted with antibodies specific for Cyclin D1, ERK, phospho-ERK, B-Raf, and Ku-70 (Santa Cruz Biotechnology)",0.85,Accept,Experimental Usage,phospho-ERK,Unknown,Unknown,,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,"Membranes were blotted with antibodies specific for Cyclin D1, ERK, phospho-ERK, B-Raf, and Ku-70 (Santa Cruz Biotechnology)",0.85,Accept,Experimental Usage,B-Raf,Unknown,Unknown,,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,"phospho-MEK1/2 [Ser217/221] and phospho Rb[S807/S811] (Cell Signaling Technology, Beverly, MA)",0.85,Accept,Experimental Usage,phospho-MEK1/2,Unknown,Unknown,,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,"phospho-MEK1/2 [Ser217/221] and phospho Rb[S807/S811] (Cell Signaling Technology, Beverly, MA)",0.85,Accept,Experimental Usage,phospho-Rb,Unknown,Unknown,,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,"Immunoblotting analysis was performed with antibodies specific for merlin (# HPA003097, Sigma-Aldrich",0.9,Accept,Experimental Usage,merlin,Unknown,Unknown,,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,"p53 (# P6874, Sigma-Aldrich; # 2524, Cell Signaling)",0.9,Accept,Experimental Usage,p53,Unknown,Unknown,,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,"MDM2 (# M43084 and # SAB4300601, Sigma-Aldrich)",0.9,Accept,Experimental Usage,MDM2,Unknown,Unknown,,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,"cyclinD1 (# C7464, Sigma-Aldrich)",0.9,Accept,Experimental Usage,cyclinD1,Unknown,Unknown,,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,"caspase-3 (# 9662, Cell Signaling)",0.9,Accept,Experimental Usage,caspase-3,Unknown,Unknown,,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,"The β-actin antibody (# AA128, Beyotime) was used to ensure equal loading of total protein",0.85,Accept,Experimental Usage,β-actin,Unknown,Unknown,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,All antibodies used in this study were purchased from Peprotech (goat anti-CXCL12,0.9,Accept,Experimental Usage,CXCL12,Unknown,Polyclonal,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,purchased from Peprotech (goat anti-CXCL12 and rabbit anti CXCL12),0.9,Accept,Experimental Usage,CXCL12,Rabbit,Polyclonal,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,Invitrogen (Rat anti-GFAP),0.9,Accept,Experimental Usage,GFAP,Unknown,Unknown,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,R&D (Goat anti-Endoglin),0.9,Accept,Experimental Usage,Endoglin,Unknown,Polyclonal,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,Wako (rabbit anti-IBA-1),0.9,Accept,Experimental Usage,IBA-1,Rabbit,Polyclonal,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,"Cell Signaling Technology (p-PKA substrate, pan-AKT and pS473-AKT)",0.9,Accept,Experimental Usage,p-PKA substrate,Unknown,Unknown,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,"Cell Signaling Technology (p-PKA substrate, pan-AKT and pS473-AKT)",0.9,Accept,Experimental Usage,AKT,Unknown,Unknown,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,"Cell Signaling Technology (p-PKA substrate, pan-AKT and pS473-AKT)",0.9,Accept,Experimental Usage,pS473-AKT,Unknown,Unknown,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,Leinco (pan-CXCR4),0.9,Accept,Experimental Usage,CXCR4,Unknown,Unknown,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,Sigma (mouse anti-CNPase),0.9,Accept,Experimental Usage,CNPase,Mouse,Monoclonal,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,Antibody directed against phosphorylated CXCR4 (pCXCR4) was developed in our lab,0.9,Accept,Experimental Usage,phosphorylated CXCR4,Unknown,Unknown,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,The rabbit anti Olig2 antibody (DF-308) was a gift from Dr. Charles Stiles,0.9,Accept,Experimental Usage,Olig2,Rabbit,Polyclonal,,,,
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,Antibodies against GAPDH (cat. no. 5174S)...were obtained from Cell Signaling Technology,0.95,Accept,Experimental Usage,GAPDH,Unknown,Unknown,,,,
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,phosphorylated PKA (cat. no. 5661S)...were obtained from Cell Signaling Technology,0.95,Accept,Experimental Usage,phosphorylated PKA,Unknown,Unknown,,,,
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,PKA (cat. no. 4782S)...were obtained from Cell Signaling Technology,0.95,Accept,Experimental Usage,PKA,Unknown,Unknown,,,,
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,phosphorylated CREB (cat. no. 9198S)...were obtained from Cell Signaling Technology,0.95,Accept,Experimental Usage,phosphorylated CREB,Unknown,Unknown,,,,
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,CREB (cat. no. 9197T) were obtained from Cell Signaling Technology,0.95,Accept,Experimental Usage,CREB,Unknown,Unknown,,,,
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,Antibody against neurofibromin (cat. no. ab17963) was purchased from Abcam,0.95,Accept,Experimental Usage,neurofibromin,Unknown,Unknown,,,,
PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,"Anti-P-glycoprotein primary antibody and Cy3-conjugated secondary antibody were purchased from Abcam (Cambridge, UK; ab170904) and Jackson ImmunoResearch",0.9,Accept,Experimental Usage,P-glycoprotein,Unknown,Unknown,,,Human,Non-conjugated
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,"primary antibody (S100 (Santa Cruz 1:100), Ki67 (Novocastra 1:200))",0.9,Accept,Experimental Usage,S100,Unknown,Unknown,,,,
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,"primary antibody (S100 (Santa Cruz 1:100), Ki67 (Novocastra 1:200))",0.9,Accept,Experimental Usage,Ki67,Unknown,Unknown,,,,
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,The primary antibodies used in this study were: p-AKT S473 (Cell Signaling 1:100),0.9,Accept,Experimental Usage,p-AKT S473,Unknown,Unknown,,,,
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,p-4EBP (Cell Signaling 1:500),0.9,Accept,Experimental Usage,p-4EBP,Unknown,Unknown,,,,
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,p-ERK (Cell Signaling 1:1000),0.9,Accept,Experimental Usage,p-ERK,Unknown,Unknown,,,,
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,GAPDH (Cell Signaling 1:2000),0.9,Accept,Experimental Usage,GAPDH,Unknown,Unknown,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,Supernatants from cleared lysates were incubated with Anti-FLAG M2 affinity gel (Sigma) to immunoprecipitated FLAG-tagged protein complexes,0.9,Accept,Experimental Usage,FLAG,Mouse,Monoclonal,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,Primary antibodies used were FLAG-M2 and KRAS (Sigma),0.9,Accept,Experimental Usage,FLAG,Mouse,Monoclonal,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,Primary antibodies used were FLAG-M2 and KRAS (Sigma),0.85,Accept,Experimental Usage,KRAS,Unknown,Unknown,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,"HA, HSP70, and Ubiquitin (Cell Signaling)",0.85,Accept,Experimental Usage,HA,Unknown,Unknown,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,"HA, HSP70, and Ubiquitin (Cell Signaling)",0.85,Accept,Experimental Usage,HSP70,Unknown,Unknown,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,"HA, HSP70, and Ubiquitin (Cell Signaling)",0.85,Accept,Experimental Usage,Ubiquitin,Unknown,Unknown,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,pan-RAS (Abcam),0.85,Accept,Experimental Usage,RAS,Unknown,Unknown,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,GST and Vinculin (Bethyl Laboratories),0.85,Accept,Experimental Usage,GST,Unknown,Unknown,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,GST and Vinculin (Bethyl Laboratories),0.85,Accept,Experimental Usage,Vinculin,Unknown,Unknown,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,RASA1 (Santa Cruz Biotechnology),0.85,Accept,Experimental Usage,RASA1,Unknown,Unknown,,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,"p-RB1-S807/811 (1:1000, no. 8516) and RB1 (no. 9309 and no. 9313, 1:500) from Cell Signaling Technology",0.95,Accept,Experimental Usage,p-RB1-S807/811,Unknown,Unknown,,,,Non-conjugated
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,"p-RB1-S807/811 (1:1000, no. 8516) and RB1 (no. 9309 and no. 9313, 1:500) from Cell Signaling Technology",0.9,Accept,Experimental Usage,RB1,Unknown,Unknown,,,,Non-conjugated
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,"p-RB1-S807/811 (1:1000, no. 8516) and RB1 (no. 9309 and no. 9313, 1:500) from Cell Signaling Technology",0.9,Accept,Experimental Usage,RB1,Unknown,Unknown,,,,Non-conjugated
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,"human p16 (ab108349, 1:1000) and GAPDH (1:5000, no. Ab8245) from Abcam",0.9,Accept,Experimental Usage,p16,Unknown,Unknown,,,Human,Non-conjugated
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,"human p16 (ab108349, 1:1000) and GAPDH (1:5000, no. Ab8245) from Abcam",0.9,Accept,Experimental Usage,GAPDH,Unknown,Unknown,,,,Non-conjugated
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,"mouse p16 (sc-1207, 1:200) from Santa Cruz Biotechnology",0.9,Accept,Experimental Usage,p16,Unknown,Unknown,,,Mouse,Non-conjugated
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,"HRP-coupled secondary antibodies (nos. NA934 and NA935, 1:2000) from Sigma",0.85,Accept,Experimental Usage,Secondary antibody,Unknown,Secondary,,,,HRP
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,"HRP-coupled secondary antibodies (nos. NA934 and NA935, 1:2000) from Sigma",0.85,Accept,Experimental Usage,Secondary antibody,Unknown,Secondary,,,,HRP
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,RABL6A antibodies (monoclonal and polyclonal) were produced in the Quelle laboratory,0.9,Accept,Experimental Usage,RABL6A,Unknown,Monoclonal,,,,Non-conjugated
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,"secondary fluorescent-conjugated antibodies (Alexa Fluor 488 and 647, 1:5000)",0.85,Accept,Experimental Usage,Secondary antibody,Unknown,Secondary,,,,Alexa Fluor 488
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,"secondary fluorescent-conjugated antibodies (Alexa Fluor 488 and 647, 1:5000)",0.85,Accept,Experimental Usage,Secondary antibody,Unknown,Secondary,,,,Alexa Fluor 647
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,Immunoprecipitations were performed using 400 µg of total protein in 1 ml IP buffer incubated with 200 μl of mAb21 anti-Nf1 monoclonal antibody supernatant,0.9,Accept,Experimental Usage,Nf1,Mouse,Monoclonal,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,"Antibodies used for immunoblotting were: anti-Nf1 (mouse, mAb21, 1:10), anti-phospho-ERK (mouse, Sigma M8159, 1:2500)",0.9,Accept,Experimental Usage,phospho-ERK,Mouse,Unknown,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,"total ERK (rabbit, CST 9102, 1:1000)",0.9,Accept,Experimental Usage,ERK,Rabbit,Unknown,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,"anti-β-tubulin (mouse, Developmental Studies Hybridoma Bank E7, 1:10,000)",0.9,Accept,Experimental Usage,β-tubulin,Mouse,Monoclonal,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,"Antibodies used were: rabbit anti-GFP (Invitrogen, A11122, 1:4000)",0.9,Accept,Experimental Usage,GFP,Rabbit,Unknown,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,"The following antibodies were used: rabbit anti-GFP (1:1000, Invitrogen), mouse anti-nc82 (1:50, DSHB)",0.9,Accept,Experimental Usage,nc82,Mouse,Unknown,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,"Immunohistochemistry (IHC) for FOXR2 (1:100, SIGMA) was performed",0.9,Accept,Experimental Usage,FOXR2,Unknown,Unknown,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,probed with antibodies against FOXR2 (SIGMA) and GAPDH (Cell Signaling Tech.),0.9,Accept,Experimental Usage,GAPDH,Unknown,Unknown,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,Immunofluorescence on tissue sections and cell lines with antibodies probing FOXR2 (SIGMA) and CNPase (Santa Cruz),0.9,Accept,Experimental Usage,CNPase,Unknown,Unknown,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,"Nuclei were then stained with 1–1.5ug (depending on pellet size) of TotalSeq™ anti-Nuclear Pore Complex Proteins Hashtag Antibody's (B0451, B0452, B0453, or B0457)",0.9,Accept,Experimental Usage,Nuclear Pore Complex Proteins,Unknown,Unknown,,,Human,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,"Nuclei were then stained with 1–1.5ug (depending on pellet size) of TotalSeq™ anti-Nuclear Pore Complex Proteins Hashtag Antibody's (B0451, B0452, B0453, or B0457)",0.9,Accept,Experimental Usage,Nuclear Pore Complex Proteins,Unknown,Unknown,,,Human,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,"Nuclei were then stained with 1–1.5ug (depending on pellet size) of TotalSeq™ anti-Nuclear Pore Complex Proteins Hashtag Antibody's (B0451, B0452, B0453, or B0457)",0.9,Accept,Experimental Usage,Nuclear Pore Complex Proteins,Unknown,Unknown,,,Human,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,"Nuclei were then stained with 1–1.5ug (depending on pellet size) of TotalSeq™ anti-Nuclear Pore Complex Proteins Hashtag Antibody's (B0451, B0452, B0453, or B0457)",0.9,Accept,Experimental Usage,Nuclear Pore Complex Proteins,Unknown,Unknown,,,Human,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,CD11b at 1:100 dilution (abcam Cat # ab52478) for myeloid cells,0.95,Accept,Experimental Usage,CD11b,Unknown,Unknown,,,Human,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,SOX10 at 1:500 dilution (abcam Cat # ab155279) for Schwann cells,0.95,Accept,Experimental Usage,SOX10,Unknown,Unknown,,,Human,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,"treated with secondary antibody Goat anti-Rabbit, Alexa Fluor™ 488 1:2000",0.85,Accept,Experimental Usage,Rabbit IgG,Unknown,Secondary,,,,Alexa Fluor 488
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,"Goat anti-Rabbit, Alexa Fluor™ 594 1:2000 for 1 h at room temperature",0.85,Accept,Experimental Usage,Rabbit IgG,Unknown,Secondary,,,,Alexa Fluor 594
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"rabbit anti-human HER1 (Abcam, ab52894)",0.9,Accept,Experimental Usage,HER1,Rabbit,Unknown,,,Human,Non-conjugated
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"rabbit anti-human HER2 (ZSGB-BIO, ZA-0023)",0.9,Accept,Experimental Usage,HER2,Rabbit,Unknown,,,Human,Non-conjugated
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"rabbit anti-human VEGFR2 (CST, 9698S)",0.9,Accept,Experimental Usage,VEGFR2,Rabbit,Unknown,,,Human,Non-conjugated
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"rabbit anti-human B7H3 (CST, #14058)",0.9,Accept,Experimental Usage,B7H3,Rabbit,Unknown,,,Human,Non-conjugated
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"rabbit anti-human CD171 (Abcam, ab208155)",0.9,Accept,Experimental Usage,CD171,Rabbit,Unknown,,,Human,Non-conjugated
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"rabbit anti-human EGFRvIII (ZSGB-BIO, ZA-0643)",0.9,Accept,Experimental Usage,EGFRvIII,Rabbit,Unknown,,,Human,Non-conjugated
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"rabbit anti-human TGFβ1 (Abcam, ab215715)",0.9,Accept,Experimental Usage,TGFβ1,Rabbit,Unknown,,,Human,Non-conjugated
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"rabbit anti-human PDL1 (Genetex, GTX104763)",0.9,Accept,Experimental Usage,PDL1,Rabbit,Unknown,,,Human,Non-conjugated
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"rabbit anti-human S100 (ZSGB-BIO, ZA-0225)",0.9,Accept,Experimental Usage,S100,Rabbit,Unknown,,,Human,Non-conjugated
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"S100β- Alexa Fluor 647 (Abcam, ab196175)",0.9,Accept,Experimental Usage,S100β,Unknown,Unknown,,,Human,Alexa Fluor 647
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"HER1-PE (352904), CD4-PE (317410), CD8a-APC (301014)",0.85,Accept,Experimental Usage,HER1,Unknown,Unknown,,,Human,PE
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"HER1-PE (352904), CD4-PE (317410), CD8a-APC (301014)",0.85,Accept,Experimental Usage,CD4,Unknown,Unknown,,,Human,PE
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"CD4-PE (317410), CD8a-APC (301014), CD45RO-PE (304206)",0.85,Accept,Experimental Usage,CD8a,Unknown,Unknown,,,Human,APC
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"CD8a-APC (301014), CD45RO-PE (304206), and CCR7-Percp (353242)",0.85,Accept,Experimental Usage,CD45RO,Unknown,Unknown,,,Human,PE
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"CD45RO-PE (304206), and CCR7-Percp (353242) (all from BioLegend)",0.85,Accept,Experimental Usage,CCR7,Unknown,Unknown,,,Human,PerCP
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,Antibodies used in western blotting targeting β-actin (#13E5),0.9,Accept,Experimental Usage,β-actin,Unknown,Monoclonal,,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,Antibodies used in western blotting targeting...MEK1/2,0.85,Accept,Experimental Usage,MEK1/2,Unknown,Unknown,,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,phospho-MEK1/2 (#41G9),0.9,Accept,Experimental Usage,phospho-MEK1/2,Unknown,Monoclonal,,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,phospho-ERK (#D13.14.4E),0.9,Accept,Experimental Usage,phospho-ERK,Unknown,Monoclonal,,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,MMP1 (#E9S9N),0.9,Accept,Experimental Usage,MMP1,Unknown,Monoclonal,,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,NF1 (#D7R7D),0.9,Accept,Experimental Usage,NF1,Unknown,Monoclonal,,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,"Antibody for Aryl hydrocarbon receptor (AHR, #H-211)",0.9,Accept,Experimental Usage,AHR,Unknown,Unknown,,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,collagen I (#EPR7785),0.9,Accept,Experimental Usage,collagen I,Unknown,Monoclonal,,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,anti-S100 protein antibody (Nichirei Biosciences Inc.),0.85,Accept,Experimental Usage,S100 protein,Unknown,Unknown,,,,
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,"Anti-CD31 (Abcam, ab7388) for vasculature",0.9,Accept,Experimental Usage,CD31,Unknown,Unknown,,,,
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,"Anti-S100B (Atlas Antibodies, HPA015768-100UL) antibodies for S100B protein",0.9,Accept,Experimental Usage,S100B,Unknown,Unknown,,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,Primary and secondary antibodies used were from Cell Signaling Technology: neurofibromin 1 (D7R7D) rabbit mAb 14623 (RRID: AB_2798543),0.95,Accept,Experimental Usage,neurofibromin 1,Rabbit,Monoclonal,,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,"anti-rabbit IgG, and horseradish peroxidase–linked secondary 7074 (RRID: AB_2099233)",0.85,Accept,Experimental Usage,rabbit IgG,,Secondary,,,,HRP
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,β-Actin was probed as a loading control using β-actin (13E5) rabbit mAb #4970 (RRID: AB_2223172),0.9,Accept,Experimental Usage,β-actin,Rabbit,Monoclonal,,,,
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,"antibodies against S100 (monoclonal, mouse, 10 μg/mL, Ventana S100-4C4.9) to demonstrate human Schwann cell origin",0.9,Accept,Experimental Usage,S100,Mouse,Monoclonal,,,,
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,"anti-Ki67 (monoclonal, mouse, 0.4 μg/mL, Ventana Ki-67-30.9) to evaluate proliferation fraction",0.9,Accept,Experimental Usage,Ki67,Mouse,Monoclonal,,,,
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,"anti-CD34 (monoclonal, mouse, 0.8 μg/mL, Ventana QBEnd/10) to demonstrate vessel and stem cell formation",0.9,Accept,Experimental Usage,CD34,Mouse,Monoclonal,,,,
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,"anti-p53 (monoclonal, mouse, Ventana Bp-53-11), anti-p16 (monoclonal, mouse, 1 μg/mL, Ventana 725-4713)",0.9,Accept,Experimental Usage,p53,Mouse,Monoclonal,,,,
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,"anti-p16 (monoclonal, mouse, 1 μg/mL, Ventana 725-4713), anti-vimentin (vimentin, monoclonal, mouse, 2.5 μg/mL, Ventana V9",0.9,Accept,Experimental Usage,p16,Mouse,Monoclonal,,,,
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,"anti-vimentin (vimentin, monoclonal, mouse, 2.5 μg/mL, Ventana V9 and anti-actin (monoclonal, mouse, 0.02 μg/mL, Cell Margue 1A4)",0.9,Accept,Experimental Usage,vimentin,Mouse,Monoclonal,,,,
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,"anti-actin (monoclonal, mouse, 0.02 μg/mL, Cell Margue 1A4). Staining was visualized using the ultraView™ Universal Alkaline Phosphatase Red Detection Kit",0.9,Accept,Experimental Usage,actin,Mouse,Monoclonal,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"Antibodies used for immunohistochemistry were against Ki67 antigen (Novocastra), glial fibrillary acidic protein (Gfap; Sigma)",0.95,Accept,Experimental Usage,Ki67 antigen,Unknown,Unknown,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"Antibodies used for immunohistochemistry were against Ki67 antigen (Novocastra), glial fibrillary acidic protein (Gfap; Sigma), Pten (NeoMarkers)",0.95,Accept,Experimental Usage,glial fibrillary acidic protein,Unknown,Unknown,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"glial fibrillary acidic protein (Gfap; Sigma), Pten (NeoMarkers), nestin (BD Bioscience)",0.95,Accept,Experimental Usage,Pten,Unknown,Unknown,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"Pten (NeoMarkers), nestin (BD Bioscience), phosphorylated Akt (p-Akt; Cell Signaling)",0.95,Accept,Experimental Usage,nestin,Unknown,Unknown,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"nestin (BD Bioscience), phosphorylated Akt (p-Akt; Cell Signaling), BrdUrd (DAKO)",0.95,Accept,Experimental Usage,phosphorylated Akt,Unknown,Unknown,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"phosphorylated Akt (p-Akt; Cell Signaling), BrdUrd (DAKO), Olig2 (Chemicon)",0.95,Accept,Experimental Usage,BrdUrd,Unknown,Unknown,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"BrdUrd (DAKO), Olig2 (Chemicon), or doublecortin (Santa Cruz)",0.95,Accept,Experimental Usage,Olig2,Unknown,Unknown,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"Olig2 (Chemicon), or doublecortin (Santa Cruz). We used microwave antigen retrieval for all antibodies, except for doublecortin antibody",0.95,Accept,Experimental Usage,doublecortin,Unknown,Unknown,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"Antibodies used were against β3-tubulin (TuJ1; Covance), Gfap (Dako), CNPase (Chemicon), or nestin",0.95,Accept,Experimental Usage,β3-tubulin,Unknown,Unknown,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"β3-tubulin (TuJ1; Covance), Gfap (Dako), CNPase (Chemicon), or nestin",0.95,Accept,Experimental Usage,Gfap,Unknown,Unknown,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"Gfap (Dako), CNPase (Chemicon), or nestin",0.95,Accept,Experimental Usage,CNPase,Unknown,Unknown,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"Antibodies used were against Pten (Cell Signaling), p-Akt, Akt, or β-actin (Sigma)",0.95,Accept,Experimental Usage,Pten,Unknown,Unknown,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"Antibodies used were against Pten (Cell Signaling), p-Akt, Akt, or β-actin (Sigma)",0.95,Accept,Experimental Usage,β-actin,Unknown,Unknown,,,,
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,optic nerve sections were incubated with polyclonal anti-S100A10 antibodies (1:1000; R&D Systems),0.85,Accept,Experimental Usage,S100A10,,Polyclonal,,,,
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,"followed by horseradish peroxidase-conjugated secondary antibodies (Vector Laboratories, Burlingame, CA, USA)",0.8,Accept,Experimental Usage,secondary antibody,,Secondary,,,,HRP
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,"Primary antibodies against Cdk1 (77055S), phospho-Cdk1 Tyr15 (9111T)... were purchased from Cell Signaling Technology",0.9,Accept,Experimental Usage,Cdk1,Rabbit,Monoclonal,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,"Primary antibodies against Cdk1 (77055S), phospho-Cdk1 Tyr15 (9111T)... were purchased from Cell Signaling Technology",0.9,Accept,Experimental Usage,phospho-Cdk1 Tyr15,Rabbit,Monoclonal,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,"Primary antibodies against... Caspase-3 (9662S), Cleaved Caspase-3 (9661S)... were purchased from Cell Signaling Technology",0.9,Accept,Experimental Usage,Caspase-3,Rabbit,Monoclonal,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,"Primary antibodies against... Caspase-3 (9662S), Cleaved Caspase-3 (9661S)... were purchased from Cell Signaling Technology",0.9,Accept,Experimental Usage,Cleaved Caspase-3,Rabbit,Monoclonal,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,"Primary antibodies against... Histone H3 (9715S), Acetyl-Histone H3 Lys18 (9675S)... were purchased from Cell Signaling Technology",0.9,Accept,Experimental Usage,Histone H3,Rabbit,Monoclonal,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,"Primary antibodies against... Histone H3 (9715S), Acetyl-Histone H3 Lys18 (9675S)... were purchased from Cell Signaling Technology",0.9,Accept,Experimental Usage,Acetyl-Histone H3 Lys18,Rabbit,Monoclonal,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,"Primary antibodies against... SAPK/JNK (9252T), phospho-SAPK/JNK Thr183/Tyr185 (4668T)... were purchased from Cell Signaling Technology",0.9,Accept,Experimental Usage,SAPK/JNK,Rabbit,Monoclonal,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,"Primary antibodies against... SAPK/JNK (9252T), phospho-SAPK/JNK Thr183/Tyr185 (4668T)... were purchased from Cell Signaling Technology",0.9,Accept,Experimental Usage,phospho-SAPK/JNK Thr183/Tyr185,Rabbit,Monoclonal,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,"Primary antibodies against... p70S6 Kinase (9202S), and phospho-p70 Thr389 S6 Kinase (9234S) were purchased from Cell Signaling Technology",0.9,Accept,Experimental Usage,p70S6 Kinase,Rabbit,Monoclonal,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,"Primary antibodies against... p70S6 Kinase (9202S), and phospho-p70 Thr389 S6 Kinase (9234S) were purchased from Cell Signaling Technology",0.9,Accept,Experimental Usage,phospho-p70 Thr389 S6 Kinase,Rabbit,Monoclonal,,,,
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,"mouse monoclonal anti-BrdU (1:800, Sigma-Aldrich, St. Louis, MO)",0.9,Accept,Experimental Usage,BrdU,Mouse,Monoclonal,,,,
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,"rabbit anti-S100 (1:800, Sigma-Aldrich, St. Louis, MO)",0.9,Accept,Experimental Usage,S100,Rabbit,Polyclonal,,,,
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,"secondary antibodies (anti-mouse Alexa Fluor 568 and anti-rabbit Alexa Fluor 488, 1:800 each, Invitrogen)",0.85,Accept,Experimental Usage,mouse IgG,,Secondary,,,,Alexa Fluor 568
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,"secondary antibodies (anti-mouse Alexa Fluor 568 and anti-rabbit Alexa Fluor 488, 1:800 each, Invitrogen)",0.85,Accept,Experimental Usage,rabbit IgG,,Secondary,,,,Alexa Fluor 488
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"co-incubation with AlexaFlour488 conjugated-pS6 (Ser240/244) antibody (Cell Signaling Technology; Beverly, MA)",0.9,Accept,Experimental Usage,phospho-S6 (Ser240/244),,,,,,Alexa Fluor 488
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"Antibodies for phospho-S6 (S240/244), S6, phospho-p70 S6K (T389)",0.9,Accept,Experimental Usage,phospho-S6 (S240/244),,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"Antibodies for phospho-S6 (S240/244), S6, phospho-p70 S6K (T389)",0.9,Accept,Experimental Usage,S6,,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"phospho-p70 S6K (T389), p70 S6K, phospho-Akt (S473)",0.9,Accept,Experimental Usage,phospho-p70 S6K (T389),,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"p70 S6K, phospho-Akt (S473), Akt",0.9,Accept,Experimental Usage,p70 S6K,,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"phospho-Akt (S473), Akt, phospho-NDRG1 (T346)",0.9,Accept,Experimental Usage,phospho-Akt (S473),,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"Akt, phospho-NDRG1 (T346), SGK1",0.9,Accept,Experimental Usage,Akt,,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"phospho-NDRG1 (T346), SGK1, phospho-PAK1 (S144)",0.9,Accept,Experimental Usage,phospho-NDRG1 (T346),,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"SGK1, phospho-PAK1 (S144), PAK1",0.9,Accept,Experimental Usage,SGK1,,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"phospho-PAK1 (S144), PAK1, and 4EBP1",0.9,Accept,Experimental Usage,phospho-PAK1 (S144),,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"PAK1, and 4EBP1 were from Cell Signaling Technology",0.9,Accept,Experimental Usage,PAK1,,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"PAK1, and 4EBP1 were from Cell Signaling Technology",0.9,Accept,Experimental Usage,4EBP1,,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"NDRG1 (Abcam; Cambridge, MA)",0.9,Accept,Experimental Usage,NDRG1,,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"Rac1 (BD Biosciences; San Jose, CA)",0.9,Accept,Experimental Usage,Rac1,,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,GAPDH (EMD Millipore),0.9,Accept,Experimental Usage,GAPDH,,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"Rheb (3M6 monoclonal; a generous gift from Richard Lamb, University of Liverpool, U.K.)",0.9,Accept,Experimental Usage,Rheb,,Monoclonal,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,the NF2 polyclonal C26 antibody has been described,0.9,Accept,Experimental Usage,NF2,,Polyclonal,,,,
PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,They were all S100-positive by immunostaining. The MPNSTs all arose from plexiform neurofibromas and showed very weak S100 immunostaining,0.85,Accept,Experimental Usage,S100,,,,,Human,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,"anti-NF1 D7R7D #14624 (Cell Signaling, rabbit, 2% BSA, 1:1000, overnight, 4 °C)",0.95,Accept,Experimental Usage,NF1,Rabbit,Monoclonal,,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,"anti-tubulin B-1-2-5 (Santa Cruz, mouse, 2% milk, 1:10000, 1 h, RT)",0.9,Accept,Experimental Usage,tubulin,Mouse,Monoclonal,,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,"anti-EGFR D38B1 #4267 (Cell Signaling, rabbit, 2% milk, 1:1000–1:2000, 1 h, RT)",0.9,Accept,Experimental Usage,EGFR,Rabbit,Monoclonal,,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,"p-ERK ½ (p44/42 MAPK) #9101 (Cell Signaling, rabbit, 2% BSA, 1:2000, overnight, 4 °C)",0.9,Accept,Experimental Usage,p-ERK,Rabbit,Unknown,,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,"SUZ12 D39F6 #3737 (Cell Signaling, rabbit, 2% milk, 1:1000, overnight, 4 °C)",0.9,Accept,Experimental Usage,SUZ12,Rabbit,Monoclonal,,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,secondary antibodies goat anti-rabbit HRP 1:20000 or goat anti-mouse HRP 1:10000 (Jackson Immunoresearch Laboratories Inc.),0.85,Accept,Experimental Usage,rabbit IgG,Unknown,Secondary,,,,HRP
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,secondary antibodies goat anti-rabbit HRP 1:20000 or goat anti-mouse HRP 1:10000 (Jackson Immunoresearch Laboratories Inc.),0.85,Accept,Experimental Usage,mouse IgG,Unknown,Secondary,,,,HRP
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,The antibodies used in this study include Pak1; Pak2; Mek1/2... (Cell Signaling Technology),0.9,Accept,Experimental Usage,Pak1,Unknown,Unknown,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,The antibodies used in this study include Pak1; Pak2; Mek1/2... (Cell Signaling Technology),0.9,Accept,Experimental Usage,Pak2,Unknown,Unknown,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,The antibodies used in this study include Pak1; Pak2; Mek1/2... (Cell Signaling Technology),0.9,Accept,Experimental Usage,Mek1/2,Unknown,Unknown,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,The antibodies used in this study include... phospho-MEK1 (Ser298)... (Cell Signaling Technology),0.95,Accept,Experimental Usage,phospho-MEK1 (Ser298),Unknown,Unknown,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,The antibodies used in this study include... Erk1/2... (Cell Signaling Technology),0.9,Accept,Experimental Usage,Erk1/2,Unknown,Unknown,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,The antibodies used in this study include... phospho-Erk1/2 (Thr202/Tyr204)... (Cell Signaling Technology),0.95,Accept,Experimental Usage,phospho-Erk1/2 (Thr202/Tyr204),Unknown,Unknown,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,The antibodies used in this study include... Akt... (Cell Signaling Technology),0.9,Accept,Experimental Usage,Akt,Unknown,Unknown,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,The antibodies used in this study include... phospho-Akt (Thr308)... (Cell Signaling Technology),0.95,Accept,Experimental Usage,phospho-Akt (Thr308),Unknown,Unknown,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,The antibodies used in this study include... Merlin (Cell Signaling Technology),0.95,Accept,Experimental Usage,Merlin,Unknown,Unknown,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,The antibodies used in this study include... phospho-Pak1–3 (Ser141; Invitrogen),0.95,Accept,Experimental Usage,phospho-Pak1–3 (Ser141),Unknown,Unknown,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,The antibodies used in this study include... GST (Santa Cruz Biotechnology),0.9,Accept,Experimental Usage,GST,Unknown,Unknown,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,The antibodies used in this study include... β-actin (Sigma),0.9,Accept,Experimental Usage,β-actin,Unknown,Unknown,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,Antibodies against DUSP6 (# ab76310) were from Abcam,0.9,Accept,Experimental Usage,DUSP6,Unknown,Unknown,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,Antibodies against cyclin D1 (sc-718 and sc-8396) were from Santa Cruz Biotechnology,0.9,Accept,Experimental Usage,cyclin D1,Unknown,Unknown,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,Antibodies against cyclin D1 (sc-718 and sc-8396) were from Santa Cruz Biotechnology,0.9,Accept,Experimental Usage,cyclin D1,Unknown,Unknown,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,"Primary antibody, anti-Ki-67 (1:200 dilution; # Ab16667, lot number GR3185488–1, Abcam)",0.9,Accept,Experimental Usage,Ki-67,Unknown,Unknown,,,,
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,"panendothelial cell antigen (550563, BD Pharmingen, USA) and anti-ratAlexa555 (A11081, Invitrogen, USA)",0.9,Accept,Experimental Usage,panendothelial cell antigen,Unknown,Unknown,,,,
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,"panendothelial cell antigen (550563, BD Pharmingen, USA) and anti-ratAlexa555 (A11081, Invitrogen, USA)",0.85,Accept,Experimental Usage,rat,Unknown,Secondary,,,,Alexa555
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"incubated overnight at 4°C with antibody: anti-S100β, Dako, Carpinteria, CA",0.9,Accept,Experimental Usage,S100β,,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"Ki67 (Novacastra Leica Microsystems, Buffalo Grove, IL)",0.9,Accept,Experimental Usage,Ki67,,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"anti-P-Stat3 (Y705), anti-cleaved caspase 3, β-catenin (Cell Signaling, Danvers, MA)",0.9,Accept,Experimental Usage,P-Stat3 (Y705),,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"anti-P-Stat3 (Y705), anti-cleaved caspase 3, β-catenin (Cell Signaling, Danvers, MA)",0.9,Accept,Experimental Usage,cleaved caspase 3,,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"anti-P-Stat3 (Y705), anti-cleaved caspase 3, β-catenin (Cell Signaling, Danvers, MA)",0.9,Accept,Experimental Usage,β-catenin,,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",0.9,Accept,Experimental Usage,P-Jak2,,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",0.9,Accept,Experimental Usage,Jak2,,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",0.9,Accept,Experimental Usage,P-Stat3,,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",0.9,Accept,Experimental Usage,Stat3,,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",0.9,Accept,Experimental Usage,P-β-catenin,,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",0.9,Accept,Experimental Usage,P-GSK3β,,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",0.9,Accept,Experimental Usage,GSK3β,,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",0.9,Accept,Experimental Usage,β-actin,,,,,,
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,"Mouse Fc receptor was blocked by TruStain FcX™ (anti-mouse CD16/32) antibody (BioLegend, Cat# 101320)",0.9,Accept,Experimental Usage,CD16/32,Unknown,Unknown,,,Mouse,
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,"endothelial, erythroid, and immune cells were gated out by PE-conjugated CD31, Ter119, and CD45 antibodies (BioLegend, Cat# 102410)",0.9,Accept,Experimental Usage,CD31,Unknown,Unknown,,,,PE
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,"endothelial, erythroid, and immune cells were gated out by PE-conjugated CD31, Ter119, and CD45 antibodies (BioLegend, Cat# 116208)",0.9,Accept,Experimental Usage,Ter119,Unknown,Unknown,,,,PE
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,"endothelial, erythroid, and immune cells were gated out by PE-conjugated CD31, Ter119, and CD45 antibodies (BioLegend, Cat# 103112)",0.9,Accept,Experimental Usage,CD45,Unknown,Unknown,,,,PE
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,cell suspensions were stained with antibodies against p75 (Ab 1554; Chemicon),0.95,Accept,Experimental Usage,p75,Unknown,Unknown,,,,
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,"antibodies against p75 (Ab 1554; Chemicon) and α 4 integrin (Becton-Dickinson, San Jose, CA)",0.9,Accept,Experimental Usage,α4 integrin,Unknown,Unknown,,,,
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,cells were stained for BrdU using a flow-cytometry kit (BD Pharmingen; cat#559619),0.9,Accept,Experimental Usage,BrdU,Unknown,Unknown,,,,
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,"Total BM cells were labeled with biotin-conjugated α-Lin Abs, consisting of α-CD3e, α-CD11b, α-CD45R/B220, α-Ly6G/Ly6C, and α-TER-119 Abs",0.9,Accept,Experimental Usage,"Lineage markers (CD3e, CD11b, CD45R/B220, Ly6G/Ly6C, TER-119)",,,,,Mouse,Biotin
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,"immunostaining with Ki67 (BD PharMingen, Pasadena CA) antibodies was performed as previously described",0.85,Accept,Experimental Usage,Ki67,Unknown,Unknown,,,,
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,"Primary phospho-histone-H3 (Ser 10) antibody was purchased from Abcam, Inc.",0.85,Accept,Experimental Usage,phospho-histone-H3 (Ser 10),Unknown,Unknown,,,,
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,"All antibodies were purchased from Cell Signaling Technology (Beverly, MD) and used at a 1:1,000 dilution",0.8,Accept,Experimental Usage,"Various (phospho-S6, phospho-4EBP1, phospho-STAT3, AKT, etc.)",Unknown,Unknown,,,,
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,"using α-tubulin (Sigma, St. Louis MO), β-actin or non-phospho-STAT3, AKT, S6, and 4EBP1 antibodies for normalization",0.85,Accept,Experimental Usage,α-tubulin,Unknown,Unknown,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,"Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology",0.9,Accept,Experimental Usage,ERK,Unknown,Unknown,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,"Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology",0.9,Accept,Experimental Usage,phospho-ERK,Unknown,Unknown,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,"Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology",0.9,Accept,Experimental Usage,phospho-MEK,Unknown,Unknown,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,"Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology",0.9,Accept,Experimental Usage,cleaved PARP,Unknown,Unknown,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,"Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology",0.9,Accept,Experimental Usage,RAD51,Unknown,Unknown,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,"Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology",0.9,Accept,Experimental Usage,BRCA2,Unknown,Unknown,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,"Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology",0.9,Accept,Experimental Usage,GAPDH,Unknown,Unknown,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,NF1 (A300–140A) was obtained from Bethyl,0.95,Accept,Experimental Usage,NF1,Unknown,Unknown,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,MGMT (sc-166528) was obtained from Santa Cruz Biotechnology,0.95,Accept,Experimental Usage,MGMT,Unknown,Unknown,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,"incubated with RAD51(1:500 no. ab133534 Abcam) or yH2AX (1:200 no. 05–636, Millipore) antibody",0.95,Accept,Experimental Usage,RAD51,Unknown,Unknown,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,"incubated with RAD51(1:500 no. ab133534 Abcam) or yH2AX (1:200 no. 05–636, Millipore) antibody",0.95,Accept,Experimental Usage,yH2AX,Unknown,Unknown,,,,
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,"The membranes were incubated with antibodies against p-AKT, total AKT, and β-Actin (SantaCruz Biotechnology, Santa Cruz, USA)",0.85,Accept,Experimental Usage,p-AKT,Unknown,Unknown,,,,
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,"The membranes were incubated with antibodies against p-AKT, total AKT, and β-Actin (SantaCruz Biotechnology, Santa Cruz, USA)",0.85,Accept,Experimental Usage,AKT,Unknown,Unknown,,,,
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,"The membranes were incubated with antibodies against p-AKT, total AKT, and β-Actin (SantaCruz Biotechnology, Santa Cruz, USA)",0.85,Accept,Experimental Usage,β-Actin,Unknown,Unknown,,,,
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,"Bound RNA and protein of interest is immunoprecipitated using the Ago2 antibody (Cell Signaling Technology, Beverly, MA, USA) at a dilution of 1:50",0.85,Accept,Experimental Usage,Ago2,Unknown,Unknown,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,Mouse monoclonal anti-rodent TRAP1 was from Becton Dickinson (Cat. #612344),0.9,Accept,Experimental Usage,TRAP1,Mouse,Monoclonal,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,mouse monoclonal anti-human TRAP1 was from Santa Cruz (Cat. #sc-73604),0.9,Accept,Experimental Usage,TRAP1,Mouse,Monoclonal,,,Human,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,mouse monoclonal anti-β actin was from Santa Cruz (Cat. #sc-47778),0.9,Accept,Experimental Usage,β actin,Mouse,Monoclonal,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,rabbit polyclonal anti-citrate synthetase was from Abcam (Cat. #ab96600),0.9,Accept,Experimental Usage,citrate synthetase,Rabbit,Polyclonal,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,rabbit polyclonal anti-HIF1α was from Novus Biologicals (Cat. #NB100-449),0.9,Accept,Experimental Usage,HIF1α,Rabbit,Polyclonal,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,rabbit polyclonal anti-HIF1α was from GeneTex (Cat. #GTX131826),0.9,Accept,Experimental Usage,HIF1α,Rabbit,Polyclonal,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,rabbit polyclonal anti-phospho-ERK1/2 was from Cell Signaling (Cat. #9101),0.9,Accept,Experimental Usage,phospho-ERK1/2,Rabbit,Polyclonal,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,rabbit polyclonal anti-glucose transporter GLUT1 was from Abcam (Cat. #ab652),0.9,Accept,Experimental Usage,GLUT1,Rabbit,Polyclonal,,,,
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,Rabbit anti-Etv5 antibody (Novus Biologicals) was diluted at 1:100 for immunohistochemistry,0.9,Accept,Experimental Usage,Etv5,Rabbit,Unknown,,,,
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,"We performed NF1 immunohistochemistry using two different NF1 antibodies (NFC, Sigma-Aldrich; and iNF-07E, iNFixion Bioscience)",0.95,Accept,Experimental Usage,NF1,Unknown,Monoclonal,,,Human,Non-conjugated
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,"We performed NF1 immunohistochemistry using two different NF1 antibodies (NFC, Sigma-Aldrich; and iNF-07E, iNFixion Bioscience)",0.95,Accept,Experimental Usage,NF1,Unknown,Monoclonal,,,Human,Non-conjugated
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,"podoplanin (clone D2-40, Dako, 1:200), phospho-ERK (#9101, Cell Signaling, 1:250)",0.9,Accept,Experimental Usage,podoplanin,Unknown,Monoclonal,,,Human,Non-conjugated
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,"podoplanin (clone D2-40, Dako, 1:200), phospho-ERK (#9101, Cell Signaling, 1:250)",0.9,Accept,Experimental Usage,phospho-ERK,Unknown,Unknown,,,Human,Non-conjugated
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,Anti-ERK1/2 (p44/42 MAPK (Erk1/2); Cell Signaling Technology; 1:1000),0.9,Accept,Experimental Usage,ERK1/2,Unknown,Unknown,,,Human,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,anti-phopho ERK1/2 (Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204); Cell Signaling Technology; 1:1000),0.9,Accept,Experimental Usage,phospho-ERK1/2,Unknown,Unknown,,,Human,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,anti-GAPDH; Santa Cruz Biotechnology Inc.; 1:3000,0.85,Accept,Experimental Usage,GAPDH,Unknown,Unknown,,,Human,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,anti-rabbit IgG HRP (Santa Cruz Biotechnology Inc.; 1:25000),0.85,Accept,Experimental Usage,rabbit IgG,Unknown,Secondary,,,,HRP
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,anti-mouse IgG HRP (Santa Cruz Biotechnology Inc.; 1:50000),0.85,Accept,Experimental Usage,mouse IgG,Unknown,Secondary,,,,HRP
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,"anti-mouse monoclonal antibodies against CD11b (8G12/HPCA-2, Becton–Dickinson; San Jose, CA) bound to allophycocyanin (APC)",0.9,Accept,Experimental Usage,CD11b,Unknown,Monoclonal,,,Mouse,APC
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,"anti-p75/NGFR (C40-1457, Becton–Dickinson) bound to phycoerythrin (PE)",0.9,Accept,Experimental Usage,p75/NGFR,Unknown,Unknown,,,Mouse,PE
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,anti-F4/80 bound to Cy5.5 on ice in a solution containing phosphate-buffered saline,0.85,Accept,Experimental Usage,F4/80,Unknown,Unknown,,,Mouse,Cy5.5
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,50 ng/mL Anti-CSF1 (R&D Systems MAB4161) in the same medium,0.9,Accept,Experimental Usage,CSF1,Unknown,Monoclonal,,,Mouse,Non-conjugated
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,rat anti-tomato (1:1000; Kerafast #EST203),0.9,Accept,Experimental Usage,tomato,Rat,Unknown,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,rabbit anti-RFP (1:1000; Rockland #600-401-379),0.9,Accept,Experimental Usage,RFP,Rabbit,Unknown,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,goat anti-CD45 (1:100; Bio-Techne #AF114),0.9,Accept,Experimental Usage,CD45,Goat,Unknown,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,goat anti-PDGFRα (1:100; R&D system #AF1062),0.9,Accept,Experimental Usage,PDGFRα,Goat,Unknown,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,rabbit anti-Ki67 (1:200; Abcam #ab15580),0.9,Accept,Experimental Usage,Ki67,Rabbit,Unknown,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,rabbit anti-P-ERK (1:250; Cell Signaling #9101),0.9,Accept,Experimental Usage,P-ERK,Rabbit,Unknown,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,goat anti-cKIT (1:100; R&D system #AF1356),0.9,Accept,Experimental Usage,cKIT,Goat,Unknown,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,rat anti-F4/80 (1:400; Abcam #ab6640),0.9,Accept,Experimental Usage,F4/80,Rat,Unknown,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,rat anti-MBP (1:200; Chemicon Millipore #MAB386),0.9,Accept,Experimental Usage,MBP,Rat,Monoclonal,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,goat anti-POSTN (1:400; BioTechne #AF2955),0.9,Accept,Experimental Usage,POSTN,Goat,Unknown,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,rabbit anti-TNC (1:100; Abcam #ab108930),0.9,Accept,Experimental Usage,TNC,Rabbit,Unknown,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,rabbit anti-PGP9.5 (1:100; Abcam #ab108986),0.9,Accept,Experimental Usage,PGP9.5,Rabbit,Unknown,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,rabbit anti-nestin (1:100; Abcam # ab221660),0.9,Accept,Experimental Usage,nestin,Rabbit,Unknown,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,mouse A488-anti-Aqp1 (1:100; Santa Cruz Biotech #sc-25287),0.9,Accept,Experimental Usage,Aqp1,Mouse,Unknown,,,,Alexa Fluor 488
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,mouse anti-S100β (1:300; Abcam #ab218516),0.9,Accept,Experimental Usage,S100β,Mouse,Unknown,,,,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,We assessed the purity of Schwann cell cultures by immunofluorescent staining with an S-100β antibody,0.85,Accept,Experimental Usage,S-100β,Unknown,Unknown,,,Human,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,"probed membranes with anti-SOX9 (Santa Cruz Biotechnology, Santa Cruz, CA; 1:700)",0.9,Accept,Experimental Usage,SOX9,Unknown,Unknown,,,Human,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,"then re-probed with anti-β-actin (Cell Signaling Technology, Inc. #4967) as a loading control",0.9,Accept,Experimental Usage,β-actin,Unknown,Unknown,,,Human,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,"We performed SOX9 immunohistochemistry on formalin-fixed, paraffin-embedded sections with polyclonal anti-SOX9 antibody (Abcam, Cambridge, UK)",0.9,Accept,Experimental Usage,SOX9,Unknown,Polyclonal,,,Human,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,Primary antibodies included N-Terminal NF1 (Cell Signaling cat# D7R7D 1:1000),0.95,Accept,Experimental Usage,NF1,,Unknown,,,Human,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,beta-actin (Cell Signaling cat# 3700 1:10000),0.95,Accept,Experimental Usage,beta-actin,,Unknown,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,p-ERK (Cell Signaling cat# 9101 1:1000),0.95,Accept,Experimental Usage,p-ERK,,Unknown,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,total ERK (Cell Signaling cat# 9102 1:1000),0.95,Accept,Experimental Usage,ERK,,Unknown,,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,"IHC was performed using a primary rabbit polyclonal anti HIF1α antibody (Novus Biologicals, Centennials, CO, USA)",0.9,Accept,Experimental Usage,HIF1α,Rabbit,Polyclonal,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,incubated with anti-KIF11 antibody (Proteintech),0.9,Accept,Experimental Usage,KIF11,Unknown,Unknown,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,anti-KIF15 antibody (Proteintech),0.9,Accept,Experimental Usage,KIF15,Unknown,Unknown,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,Ki67 (Ventana Medical Systems),0.9,Accept,Experimental Usage,Ki67,Unknown,Unknown,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,anti-α-tubulin (Sigma-Aldrich),0.9,Accept,Experimental Usage,α-tubulin,Unknown,Unknown,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,anti-α-tubulin-Alexa488 antibody (Life Technologies),0.9,Accept,Experimental Usage,α-tubulin,Unknown,Unknown,,,,Alexa Fluor 488
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,"PGDS immunohistochemistry was carried out on adjacent paraffin sections using affinity‐purified rabbit polyclonal antibodies (1:500; Santa Cruz, CA, USA sc‐14825)",0.9,Accept,Experimental Usage,PGDS,Rabbit,Polyclonal,,,,
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,"Antibodies against phospho-AKT (S473), total AKT, and monoclonal rabbit anti-phospho-S6K (T389) were from Cell Signaling Technology",0.9,Accept,Experimental Usage,phospho-AKT (S473),Unknown,Unknown,,,,
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,"Antibodies against phospho-AKT (S473), total AKT, and monoclonal rabbit anti-phospho-S6K (T389) were from Cell Signaling Technology",0.9,Accept,Experimental Usage,AKT,Unknown,Unknown,,,,
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,"Antibodies against phospho-AKT (S473), total AKT, and monoclonal rabbit anti-phospho-S6K (T389) were from Cell Signaling Technology",0.9,Accept,Experimental Usage,phospho-S6K (T389),Rabbit,Monoclonal,,,,
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,Total S6K1 antibody was used as previously described,0.9,Accept,Experimental Usage,S6K1,Unknown,Unknown,,,,
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,Sections were incubated with rat anti-CD31 antibodies (BD bioscience) at 1:40 dilution for 60 min at room temperature,0.9,Accept,Experimental Usage,CD31,Unknown,Unknown,,,,
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,"For Mib1 detection, paraffin sections were treated with TRS or antigen retrieval followed by a prediluted Mib1 antibody (DAKO)",0.9,Accept,Experimental Usage,Mib1,Unknown,Unknown,,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Antibodies were obtained from Peprotech (CXCL12),0.8,Accept,Experimental Usage,CXCL12,Unknown,Unknown,,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Clontech (Dsred (mCherry)),0.8,Accept,Experimental Usage,mCherry,Unknown,Unknown,,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Invitrogen (GFAP),0.8,Accept,Experimental Usage,GFAP,Unknown,Unknown,,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Abcam (PDE4A & 58kD Golgi marker),0.8,Accept,Experimental Usage,PDE4A,Unknown,Unknown,,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Pharmingen (LCA),0.8,Accept,Experimental Usage,LCA,Unknown,Unknown,,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Wako (IBA-1),0.8,Accept,Experimental Usage,IBA-1,Unknown,Unknown,,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Cell Signaling (phosphorylated protein kinase A (pPKA) substrate),0.8,Accept,Experimental Usage,phosphorylated protein kinase A substrate,Unknown,Unknown,,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Sigma (CNPase),0.8,Accept,Experimental Usage,CNPase,Unknown,Unknown,,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Antibody directed against phosphorylated CXCR4 (pCXCR4) was developed in our lab and previously described,0.8,Accept,Experimental Usage,phosphorylated CXCR4,Unknown,Unknown,,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Antibody directed against Olig2 (DF-308) was a gift of Dr. Charles Stiles (Dana Farber Cancer Institute),0.85,Accept,Experimental Usage,Olig2,Unknown,Unknown,,,,
PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the ,,Depletion of neutrophils via anti-Ly6G antibody or bone marrow suppression using hydroxyurea significantly improved tumor clearance.,0.9,Accept,Experimental Usage,Ly6G,Unknown,Unknown,,,Mouse,Non-conjugated
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,"incubated for 30 minutes on ice with unconjugated primary antibody p75 (1:1,000, Ab3125, Abcam)",0.95,Accept,Experimental Usage,p75,,Unknown,,,,Non-conjugated
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,"incubated with primary antibodies, p75 (1:100, Ab3125, Abcam), S100B (1:1,000, Z0311, Dako)",0.95,Accept,Experimental Usage,S100B,,Unknown,,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,"MPZ (1:100, Ab183868, Abcam), overnight at 4ºC",0.95,Accept,Experimental Usage,MPZ,,Unknown,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,"CD31 (3528S, 1:100, Cell Signaling)",0.9,Accept,Experimental Usage,CD31,Unknown,Unknown,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,"Survivin (MA5–15077, 1:200, Invitrogen)",0.9,Accept,Experimental Usage,Survivin,Unknown,Unknown,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,"CENPF (PA5–84637, 1:200, Invitrogen)",0.9,Accept,Experimental Usage,CENPF,Unknown,Unknown,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,"H3K27me3 (9733S, 1:100, Cell Signaling)",0.9,Accept,Experimental Usage,H3K27me3,Unknown,Unknown,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,"CENPF (ab223847, 1:1000 dilution, Abcam)",0.9,Accept,Experimental Usage,CENPF,Unknown,Unknown,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,"Vinculin (ab219649, 1:1000 dilution, Abcam)",0.9,Accept,Experimental Usage,Vinculin,Unknown,Unknown,,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,"followed by either Alexa-Fluor-tagged secondary antibodies (Invitrogen, Grand Island, NY)",0.8,Accept,Experimental Usage,secondary antibody,,Secondary,,,,Alexa Fluor
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,or biotinylated secondary antibodies and Vectastain Elite ABC development,0.8,Accept,Experimental Usage,secondary antibody,,Secondary,,,,biotin
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,CD34 Santa Cruz Biotechnology CAT#SC-74499; RRID: AB_1120394,0.9,Accept,Experimental Usage,CD34,Unknown,Unknown,,,Unknown,Non-conjugated
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,CD56 Biocare Medical CAT#CM164A,0.9,Accept,Experimental Usage,CD56,Mouse,Unknown,,,Unknown,Non-conjugated
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,CD117/c-kit Biocare Medical CAT#CME296AK; RRID: AB_10581782,0.9,Accept,Experimental Usage,CD117/c-kit,Rabbit,Unknown,,,Unknown,Non-conjugated
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,NGFR Biocare Medical CAT#ACI369A,0.9,Accept,Experimental Usage,NGFR,Rabbit,Unknown,,,Unknown,Non-conjugated
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,PanCytokeratin Biocare Medical CAT#CM011A; RRID: AB_2811020,0.9,Accept,Experimental Usage,PanCytokeratin,Mouse,Unknown,,,Unknown,Non-conjugated
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,SOX2 Biocare Medical CAT#ACI3109A,0.9,Accept,Experimental Usage,SOX2,Mouse,Unknown,,,Unknown,Non-conjugated
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,SOX10 Biocare Medical CAT#ACI3099A,0.9,Accept,Experimental Usage,SOX10,Mouse,Unknown,,,Unknown,Non-conjugated
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,S100 Biocare Medical CAT#ACI3237A,0.9,Accept,Experimental Usage,S100,Mouse,Unknown,,,Unknown,Non-conjugated
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,APC Anti-c-Kit antibody [YB5.B8] (ab95678),0.9,Accept,Experimental Usage,c-Kit,Unknown,Monoclonal,,,Unknown,APC
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,Recombinant PE Anti-S100A11 antibody [EPR11172] (ab211996),0.9,Accept,Experimental Usage,S100A11,Unknown,Recombinant,,,Unknown,PE
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,FITC Anti-CD34 antibody [4H11[APG]] (ab18227),0.9,Accept,Experimental Usage,CD34,Unknown,Monoclonal,,,Unknown,FITC
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"H3K27me3 (Cell Signaling Technology, #9733, clone C36B11, 1:50 dilution)",0.9,Accept,Experimental Usage,H3K27me3,,Monoclonal,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"SOX10 (Cell Marque, #383R-1, clone EP268, 1:50 dilution)",0.9,Accept,Experimental Usage,SOX10,,Monoclonal,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"S100B (Ventana, #760-2523, 1:2 dilution)",0.9,Accept,Experimental Usage,S100B,,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"pERK (Cell Signaling Technologies, #4370, 1:1000 dilution)",0.9,Accept,Experimental Usage,pERK,,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"total ERK (Cell Signaling Technologies, #4695, 1:1000 dilution)",0.9,Accept,Experimental Usage,ERK,,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"beta tubulin (Developmental Hybridoma Studies Bank, #E7, 1:10,000 dilution)",0.9,Accept,Experimental Usage,beta tubulin,,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"pAKT (Cell Signaling Technologies, #4060, 1:1000 dilution)",0.9,Accept,Experimental Usage,pAKT,,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"total AKT (Cell Signaling Technologies, # 4685, 1:1000 dilution)",0.9,Accept,Experimental Usage,AKT,,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"pMEK (Cell Signaling Technologies, #9121, 1:1000 dilution)",0.9,Accept,Experimental Usage,pMEK,,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"total MEK (Cell Signaling Technologies, #8727, 1:1000 dilution)",0.9,Accept,Experimental Usage,MEK,,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"pPAK (Cell Signaling Technologies, #2601, 1:1000 dilution)",0.9,Accept,Experimental Usage,pPAK,,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"Caspase-3 (Cell Signaling Technologies, #9662, 1:1000 dilution)",0.9,Accept,Experimental Usage,Caspase-3,,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"Caspase-7 (Cell Signaling Technologies, #9492, 1:1,000 dilution)",0.9,Accept,Experimental Usage,Caspase-7,,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"NF2/Merlin (Abcam, #ab88957, clone AF1G4, 1:2000 dilution)",0.9,Accept,Experimental Usage,NF2/Merlin,,Monoclonal,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,ALDH1A1 (1:200; ab52492; Abcam),0.9,Accept,Experimental Usage,ALDH1A1,Unknown,Unknown,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,YAP (1:100; #14074; CST),0.9,Accept,Experimental Usage,YAP,Unknown,Unknown,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,TAZ (1:100; sc-48805; Santa Cruz),0.9,Accept,Experimental Usage,TAZ,Unknown,Unknown,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Ki67 (1:100; ab15580; Abcam),0.9,Accept,Experimental Usage,Ki67,Unknown,Unknown,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Neurofilament (1:1000; ab4680; Abcam),0.9,Accept,Experimental Usage,Neurofilament,Unknown,Unknown,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,S100 (pre-diluted; GA504; Dako),0.9,Accept,Experimental Usage,S100,Unknown,Unknown,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Pan-TEAD (1:1000; #13295; CST),0.9,Accept,Experimental Usage,Pan-TEAD,Unknown,Unknown,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,GAPDH (1:5000; AB2302; Merck),0.9,Accept,Experimental Usage,GAPDH,Unknown,Unknown,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,"CTGF (1:500, ab6992, Abcam)",0.9,Accept,Experimental Usage,CTGF,Unknown,Unknown,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,"Rabbit anti-EGFR, Notch1 (Cell Signaling), and rabbit anti S518-Merlin (Abcam and Cell Signaling) were used at 1:1000 dilution",0.9,Accept,Experimental Usage,EGFR,Rabbit,Unknown,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,"Rabbit anti-EGFR, Notch1 (Cell Signaling), and rabbit anti S518-Merlin (Abcam and Cell Signaling) were used at 1:1000 dilution",0.9,Accept,Experimental Usage,Notch1,Rabbit,Unknown,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,rabbit anti S518-Merlin (Abcam and Cell Signaling) were used at 1:1000 dilution,0.9,Accept,Experimental Usage,S518-Merlin,Rabbit,Unknown,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,rabbit anti S518-Merlin (Abcam and Cell Signaling) were used at 1:1000 dilution,0.9,Accept,Experimental Usage,S518-Merlin,Rabbit,Unknown,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,"Markers for membrane, cytosolic and nuclear fractions were: rabbit anti- Na + , K + - ATPase, GAPDH, and PARP (Cell Signaling)",0.85,Accept,Experimental Usage,"Na+,K+-ATPase",Rabbit,Unknown,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,"Markers for membrane, cytosolic and nuclear fractions were: rabbit anti- Na + , K + - ATPase, GAPDH, and PARP (Cell Signaling)",0.85,Accept,Experimental Usage,GAPDH,Unknown,Unknown,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,"Markers for membrane, cytosolic and nuclear fractions were: rabbit anti- Na + , K + - ATPase, GAPDH, and PARP (Cell Signaling)",0.85,Accept,Experimental Usage,PARP,Unknown,Unknown,,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,An actin immunocytochemistry assay was performed to study the cytoskeletal organization after PMO treatment using Phalloidin (Molecular Probes),0.9,Accept,Experimental Usage,Actin,,Unknown,,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,"Flag expression was assessed by western blot (Monoclonal ANTI-FLAG M2 antibody, Sigma-Aldrich, St. Louis, MO)",0.95,Accept,Experimental Usage,FLAG,Mouse,Monoclonal,,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,"The primary antibodies used were anti-NeuroD1 (Abcam, ab109224) and anti-β-actin (Sigma, A5316)",0.95,Accept,Experimental Usage,NeuroD1,Unknown,Unknown,,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,"The primary antibodies used were anti-NeuroD1 (Abcam, ab109224) and anti-β-actin (Sigma, A5316)",0.95,Accept,Experimental Usage,β-actin,Unknown,Unknown,,,,
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,"Ras was detected with a 1:250 dilution of anti-pan Ras monoclonal antibody (BD Transduction Laboratories, San Jose, CA)",0.9,Accept,Experimental Usage,Ras,Mouse,Monoclonal,,,,
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,"Caspase-3 was detected with a 1:1000 dilution of anti-Caspase-3 polycolonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA)",0.9,Accept,Experimental Usage,Caspase-3,,Polyclonal,,,,
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,"Retinoblastoma protein (pRb) phosphorylated Serine 780 was detected with a 1:1000 dilution of anti-Phospho-Rb Ser 780 polyclonal antibody (Cell Signaling Technology, Danvers, MA)",0.9,Accept,Experimental Usage,Phospho-Rb Ser 780,,Polyclonal,,,,
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,"β-Tubulin was immunoblotted with a 1:2000 dilution of the E7 monoclonal antibody (Developmental Studies Hybridoma Bank, Iowa City, IA)",0.9,Accept,Experimental Usage,β-Tubulin,Mouse,Monoclonal,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,"Antibody anti-pSmad3, rabbit monoclonal Abcam Cat. # ab52903 RRID: AB_882596 1/200 dilution",0.9,Accept,Experimental Usage,pSmad3,Rabbit,Monoclonal,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,"Antibody Zpr-1, mouse monoclonal Zebrafish International Resource Center Cat. # zpr-1 RRID: AB_10013803",0.9,Accept,Experimental Usage,Zpr-1,Mouse,Monoclonal,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,"Antibody Zn-5, mouse monoclonal Zebrafish International Resource Center Cat. # zn-5 RRID: AB_10013770",0.9,Accept,Experimental Usage,Zn-5,Mouse,Monoclonal,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,"Antibody anti-HuC/D, rabbit polyclonal Abcam Cat. # ab210554 RRID: AB_210554 1/500 dilution",0.9,Accept,Experimental Usage,HuC/D,Rabbit,Polyclonal,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,"Antibody anti-PKC β1, mouse monoclonal Santa Cruz Biotechnology Cat. # SC-8049 RRID: AB_628143",0.9,Accept,Experimental Usage,PKC β1,Mouse,Monoclonal,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,"Antibody anti-glutamine synthetase (GS), mouse monoclonal Sigma-Aldrich Cat. # MAB302 RRID: AB_2110656",0.9,Accept,Experimental Usage,glutamine synthetase,Mouse,Monoclonal,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,"Antibody anti-SOX9, rabbit polyclonal Millipore Sigma Cat. # AB5535 RRID: AB_2239761 1/500 dilution",0.9,Accept,Experimental Usage,SOX9,Rabbit,Polyclonal,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,"Antibody anti-BrdU, rat monoclonal Thermo Fisher Cat. # MA 182088 RRID: AB_927214 1/500 dilution",0.9,Accept,Experimental Usage,BrdU,Rat,Monoclonal,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,"Antibody anti-BrdU, mouse monoclonal Thermo Fisher Cat. # B35128 RRID: AB_2536432 Clone MoBu-1",0.9,Accept,Experimental Usage,BrdU,Mouse,Monoclonal,,,,
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,incubated with primary antibodies overnight at 4°C: S100-fluorescein isothiocyanate (FITC) (major protein expressed by C6 cells),0.9,Accept,Experimental Usage,S100,,,,,,FITC
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,β-tubulin III-FITC (neurofibroma presence),0.9,Accept,Experimental Usage,β-tubulin III,,,,,,FITC
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,Ki67-FITC (proliferation marker),0.9,Accept,Experimental Usage,Ki67,,,,,,FITC
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,Vimentin-antigen presenting cell (APC) (expressed by C6 cells),0.9,Accept,Experimental Usage,Vimentin,,,,,,APC
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,Foxp3-APC and CD45 (immune response markers),0.9,Accept,Experimental Usage,Foxp3,,,,,,APC
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,Foxp3-APC and CD45 (immune response markers),0.9,Accept,Experimental Usage,CD45,,,,,,
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,"labeled overnight at room temperature with the following conjugated primary antibodies: S100-FITC, Vimentin-FTIC, CD45-APC, Ki67-APC, and GFAP-APC",0.9,Accept,Experimental Usage,GFAP,,,,,,APC
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,"Human S-100 A and B protein was detected using rabbit antiserum (Dako Corp, Carpinteria, Calif)",0.85,Accept,Experimental Usage,S-100,Rabbit,Unknown,,,Human,Non-conjugated
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,The rabbit anti-S-100 antibodies were detected using affinity purified biotinylated F(ab')2 swine anti-rabbit IgG (Dako),0.8,Accept,Experimental Usage,rabbit IgG,Unknown,Secondary,,,Rabbit,Biotin
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,followed by horseradish peroxidase-conjugated streptavidin (Dako),0.8,Accept,Experimental Usage,biotin,Unknown,Secondary,,,,HRP
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,"Fluorescein-conjugated IB4 (Vector Laboratories, Burlingame, Calif) diluted in PBS",0.85,Accept,Experimental Usage,Gal α 1-3Gal,Unknown,Unknown,,,Non-primate,Fluorescein
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,"Western blots and immunohistochemistry (IHC) using DARPP32, p-MAPK, total MAPK (Cell Signaling)",0.9,Accept,Experimental Usage,DARPP32,Unknown,Unknown,,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,"Western blots and immunohistochemistry (IHC) using DARPP32, p-MAPK, total MAPK (Cell Signaling)",0.9,Accept,Experimental Usage,p-MAPK,Unknown,Unknown,,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,"Western blots and immunohistochemistry (IHC) using DARPP32, p-MAPK, total MAPK (Cell Signaling)",0.9,Accept,Experimental Usage,total MAPK,Unknown,Unknown,,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,total MAPK (Cell Signaling) and p-DARPP32 (Abcam) antibodies,0.9,Accept,Experimental Usage,p-DARPP32,Unknown,Unknown,,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,"incubated with a monoclonal anti-Cy3/Cy5 antibody (ab52060, Abcam, 1:2500) for 1 h at room temperature",0.9,Accept,Experimental Usage,Cy3/Cy5,,Monoclonal,,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,"using an ATRX antibody (Rabbit polyclonal, 1:200 dilution, catalog# HPA001906 Sigma-Aldrich)",0.95,Accept,Experimental Usage,ATRX,Rabbit,Polyclonal,,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,"Immunohistochemistry for DAXX (Rabbit polyclonal, 1:100 dilution, catalog# HPA008736, Atlas Antibodies) was performed manually",0.95,Accept,Experimental Usage,DAXX,Rabbit,Polyclonal,,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,"using a mouse monoclonal antibody (Abcam, Cat# ab6002, Cambridge, MA) at 1:1600 dilution",0.95,Accept,Experimental Usage,H3K27me3,Mouse,Monoclonal,,,,
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,"The cells were labeled with Alexa Fluor 647-conjugated anti-phospho-ERK1/2 primary antibody (Cell Signaling Technology, MA, USA)",0.95,Accept,Experimental Usage,phospho-ERK1/2,,,,,Human,Alexa Fluor 647
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,The embryos were incubated in anti-pH3 antibody overnight at 4°C,0.8,Accept,Experimental Usage,pH3,Unknown,Unknown,,,,
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,"The next day, the samples were washed in PBS–Triton-X100 (4×30 min) at room temperature and incubated in a secondary antibody (Thermo Fisher Scientific, A21202) for 4 h at room temperature",0.85,Accept,Experimental Usage,Unknown,Unknown,Secondary,,,,
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,"Subsequently, the blot was incubated with a 1:1000 dilution of anti-merlin antibody overnight at 4°C",0.9,Accept,Experimental Usage,merlin,Unknown,Unknown,,,,
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,Anti-Sox10 antibody staining on HCR-processed sections was performed according to Kamenev et al. (2021),0.85,Accept,Experimental Usage,Sox10,Unknown,Unknown,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,"following Biolegend antibodies and stains: anti-human HLA-A,B,C (311405)",0.9,Accept,Experimental Usage,"HLA-A,B,C",,,,,Human,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,"anti-mouse H-2 (125505), Mouse IgG1, κ Isotype Ctrl (FC) Antibody",0.9,Accept,Experimental Usage,H-2,,,,,Mouse,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,"using the following antibodies: human nuclei (ab254080, Abcam)",0.9,Accept,Experimental Usage,human nuclei,,,,,Human,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,"Ki-67 (RM9106S1, Fisher Scientific), S-100 b (sc-393919, Santa Cruz Biotechnology)",0.9,Accept,Experimental Usage,Ki-67,,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,"Ki-67 (RM9106S1, Fisher Scientific), S-100 b (sc-393919, Santa Cruz Biotechnology)",0.9,Accept,Experimental Usage,S-100 b,,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,"H3K27me3 (9733, Cell Signaling Technologies), pERK (4370, Cell Signaling Technologies)",0.9,Accept,Experimental Usage,H3K27me3,,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,"H3K27me3 (9733, Cell Signaling Technologies), pERK (4370, Cell Signaling Technologies)",0.9,Accept,Experimental Usage,pERK,,,,,,
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,"A recombinant anti-FAP antibody (clone ab207178, Abcam, Cambridge, UK) was applied at a dilution of 1:250",0.9,Accept,Experimental Usage,FAP,Unknown,Recombinant,,,Human,Non-conjugated
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,"primary antibodies for LAMA2 (Abnova (Catalog #: H00003908-M01), 1:1000)",0.95,Accept,Experimental Usage,LAMA2,,,,,,
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,"SLC22A3 (Novus Biologicals (Catalog #: NBP1-83976), 1:750)",0.95,Accept,Experimental Usage,SLC22A3,,,,,,
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,"PRRX1 (Thermo Fisher Scientific (Catalog#: MA5-26580), 1:200)",0.95,Accept,Experimental Usage,PRRX1,,,,,,
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,"SOX10 (Roche (Catalog#: 760-4968), pre-diluted kit)",0.95,Accept,Experimental Usage,SOX10,,,,,,
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,Primary antibodies against Phospho-p44/42 ERK1/2 (p-ERK) (Cell Signaling Technologies #4370S) and p44/42 ERK1/2 (ERK) (Cell Signaling Technologies #4695S) were used at 1:100 dilution,0.95,Accept,Experimental Usage,Phospho-p44/42 ERK1/2,Rabbit,Monoclonal,,,,
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,Primary antibodies against Phospho-p44/42 ERK1/2 (p-ERK) (Cell Signaling Technologies #4370S) and p44/42 ERK1/2 (ERK) (Cell Signaling Technologies #4695S) were used at 1:100 dilution,0.95,Accept,Experimental Usage,p44/42 ERK1/2,Rabbit,Monoclonal,,,,
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,"Immunohistochemical staining for phosphor-p44/p42 MAPK (ERK1/2) (Thr202/Tyr204) (Cell Signaling Technology Catalog #4370, Rabbit mAb, 1:100 dilution)",0.95,Accept,Experimental Usage,phosphor-p44/p42 MAPK (ERK1/2),Rabbit,Monoclonal,,,,
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,"Western blots were performed using pDARPP32 (1:500, Cell Signaling), DARPP32 (1:1000, Cell Signaling)",0.85,Accept,Experimental Usage,pDARPP32,Unknown,Unknown,,,,
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,"Western blots were performed using pDARPP32 (1:500, Cell Signaling), DARPP32 (1:1000, Cell Signaling)",0.85,Accept,Experimental Usage,DARPP32,Unknown,Unknown,,,,
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,"pERK1/2 (1:1000, Cell Signaling), and ERK1/2 (1:1000, Cell Signaling) primary antibodies",0.85,Accept,Experimental Usage,pERK1/2,Unknown,Unknown,,,,
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,"pERK1/2 (1:1000, Cell Signaling), and ERK1/2 (1:1000, Cell Signaling) primary antibodies",0.85,Accept,Experimental Usage,ERK1/2,Unknown,Unknown,,,,
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,"KRAS (Sigma; WH0003845M1, clone 3B10-2F2; does not detect proteins with E162L mutation)",0.9,Accept,Experimental Usage,KRAS,Mouse,Monoclonal,,,,
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,"EGFP (Thermo Fisher Scientific; 11575712, clone F56-6A1.2.3)",0.9,Accept,Experimental Usage,EGFP,Mouse,Monoclonal,,,,
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,"p-ERK1/2 (CST 4370, clone D13.14.4E)",0.9,Accept,Experimental Usage,p-ERK1/2,Rabbit,Monoclonal,,,,
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,"ERK1/2 (CST 9107, clone 3A7)",0.9,Accept,Experimental Usage,ERK1/2,Mouse,Monoclonal,,,,
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,"using an anti-Phospho-ERK1/2 antibody (Cell Signaling cat#9101, dilution 1:1000)",0.9,Accept,Experimental Usage,Phospho-ERK1/2,Unknown,Unknown,,,,
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,"ananti-ERK1/2 antibody (Cell Signaling cat#9102, dilution 1:1000)",0.9,Accept,Experimental Usage,ERK1/2,Unknown,Unknown,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,overnight incubation in a 1:250 dilution of total c-met rabbit polyclonal antibody (Santa Cruz),0.9,Accept,Experimental Usage,c-Met,Rabbit,Polyclonal,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,"1:50 dilution of phosphorylated c-met (phosphorylated tyrosine sites pY1230, pY1234, and pY1236) rabbit polyclonal antibody (Invitrogen)",0.9,Accept,Experimental Usage,phosphorylated c-Met,Rabbit,Polyclonal,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,Other slides were stained in a 1:100 dilution of Ki67 rat monoclonal antibody (Dako),0.9,Accept,Experimental Usage,Ki67,Rat,Monoclonal,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,Additional slides were incubated with antibodies against pan-cytokeratin and cytokeratin 8 (Sigma),0.85,Accept,Experimental Usage,pan-cytokeratin,,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,Additional slides were incubated with antibodies against pan-cytokeratin and cytokeratin 8 (Sigma),0.85,Accept,Experimental Usage,cytokeratin 8,,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,Additional slides were incubated with antibodies against pan-cytokeratin and cytokeratin 8 (Sigma) or mesothelin (Santa Cruz),0.85,Accept,Experimental Usage,mesothelin,,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,"Other sections were stained with antibodies against Sox2, Nanog, Oct 3/4 and beta-catenin",0.8,Accept,Experimental Usage,Sox2,,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,"Other sections were stained with antibodies against Sox2, Nanog, Oct 3/4 and beta-catenin",0.8,Accept,Experimental Usage,Nanog,,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,"Other sections were stained with antibodies against Sox2, Nanog, Oct 3/4 and beta-catenin",0.8,Accept,Experimental Usage,Oct 3/4,,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,"Other sections were stained with antibodies against Sox2, Nanog, Oct 3/4 and beta-catenin",0.8,Accept,Experimental Usage,beta-catenin,,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,"Antibodies against phospho P-Met, Akt, P-Akt, and MAPK (1:1,000 dilution), from Cell Signaling",0.9,Accept,Experimental Usage,phospho P-Met,,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,"Antibodies against phospho P-Met, Akt, P-Akt, and MAPK (1:1,000 dilution), from Cell Signaling",0.9,Accept,Experimental Usage,Akt,,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,"Antibodies against phospho P-Met, Akt, P-Akt, and MAPK (1:1,000 dilution), from Cell Signaling",0.9,Accept,Experimental Usage,P-Akt,,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,"Antibodies against phospho P-Met, Akt, P-Akt, and MAPK (1:1,000 dilution), from Cell Signaling",0.9,Accept,Experimental Usage,MAPK,,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,"and against c-Met, P-Erk and β-actin (1:1,000), from Santa Cruz",0.9,Accept,Experimental Usage,c-Met,,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,"and against c-Met, P-Erk and β-actin (1:1,000), from Santa Cruz",0.9,Accept,Experimental Usage,P-Erk,,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,"and against c-Met, P-Erk and β-actin (1:1,000), from Santa Cruz",0.9,Accept,Experimental Usage,β-actin,,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,"and p53 (1:500, NCL-p53-505, Novocastra) were used",0.9,Accept,Experimental Usage,p53,,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,1 × 106 MM cells were incubated with or without 10 μL of anti-CD24 FITC-labeled antibody (BD Biosciences),0.9,Accept,Experimental Usage,CD24,,,,,,FITC
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,The anti-p55 mouse monoclonal antibody was generated by immunizing BALB/c mice with the recombinant SH3-GUK segment of human erythrocyte p55 protein. The clone 2G4 was selected,0.9,Accept,Development,p55/MPP1,Mouse,Monoclonal,,,Human,Non-conjugated
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,Another anti-merlin polyclonal antibody (A-19) was purchased from Santa Cruz Biotechnology,0.85,Accept,Experimental Usage,NF2/merlin,Unknown,Polyclonal,,,Human,Non-conjugated
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,The following primary antibodies were used: rabbit anti-NF2 (Santa Cruz); mouse anti-p55 monoclonal (this study); mouse anti-S100 (SIGMA),0.8,Accept,Experimental Usage,S100,Mouse,Unknown,,,Human,Non-conjugated
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,mouse anti-GFAP (Chemicon) and rabbit anti-GFAP (SIGMA),0.8,Accept,Experimental Usage,GFAP,Mouse,Unknown,,,Human,Non-conjugated
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,mouse anti-GFAP (Chemicon) and rabbit anti-GFAP (SIGMA),0.8,Accept,Experimental Usage,GFAP,Rabbit,Polyclonal,,,Human,Non-conjugated
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,rabbit anti-NF-H (Chemicon); and mouse anti-Caspr,0.8,Accept,Experimental Usage,NF-H,Rabbit,Polyclonal,,,Human,Non-conjugated
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,"and mouse anti-Caspr, kindly provided by Dr. Elior Peles, The Weizmann Institute of Science, Rehovot, Israel",0.8,Accept,Experimental Usage,Caspr,Mouse,Unknown,,,Human,Non-conjugated
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3...",0.9,Accept,Experimental Usage,CD3,Unknown,Unknown,,,Human,Unknown
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3...",0.9,Accept,Experimental Usage,CD8,Unknown,Unknown,,,Human,Unknown
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3...",0.9,Accept,Experimental Usage,CD11c,Unknown,Unknown,,,Human,Unknown
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3...",0.9,Accept,Experimental Usage,CD19,Unknown,Unknown,,,Human,Unknown
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3...",0.9,Accept,Experimental Usage,CD163,Unknown,Unknown,,,Human,Unknown
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3...",0.9,Accept,Experimental Usage,CSF1R,Unknown,Unknown,,,Human,Unknown
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3...",0.9,Accept,Experimental Usage,FOXP3,Unknown,Unknown,,,Human,Unknown
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3, human leukocyte antigen (HLA)-class I, and PD-L1",0.9,Accept,Experimental Usage,PD-L1,Unknown,Unknown,,,Human,Unknown
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,"IHC for H3K27me3 (Cell Signaling Technology, #9733, clone C36B11, 1:100 dilution) was performed on FFPE whole slide tissue sections",0.95,Accept,Experimental Usage,H3K27me3,Unknown,Monoclonal,,,Human,Unknown
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,"Fibroblasts were stained for 30 min at 4°C with 1 µg/ml of FITC-conjugated anti-ColIA monoclonal antibody (Pharmingen, San Diego, CA, USA)",0.85,Accept,Experimental Usage,ColIA,,Monoclonal,,,,FITC
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,"All tissues were sectioned (5 µm thickness), mounted onto slides and stained with PE-conjugated anti-ColIA antibody and counterstained with DAPI",0.85,Accept,Experimental Usage,ColIA,,,,,,PE
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,"equivalent protein (500 µg) was incubated overnight at 4°C with anti-Abl (K12; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA)",0.9,Accept,Experimental Usage,Abl,,,,,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,"equivalent protein (500 µg) was incubated overnight at 4°C with anti-Abl (K12; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) or anti-Flag (Sigma-Aldrich)",0.85,Accept,Experimental Usage,Flag,,,,,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,"Total c-abl protein was detected using an antibody from BD Biosciences (Cat. no. 554148, San Jose, CA, USA)",0.9,Accept,Experimental Usage,c-abl,,,,,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,"TGF-β neutralizing antibodies were obtained from R&D Systems, Inc. (Cat. no. AF-101-NA) and utilized as suggested by the manufacturer",0.9,Accept,Experimental Usage,TGF-β,,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,"Anti-Nestin antibody primary IF CST (Danvers, USA)",0.85,Accept,Experimental Usage,Nestin,,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Anti-SOX2 antibody primary IF CST,0.85,Accept,Experimental Usage,SOX2,,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Anti-MAP2 antibody primary IF and WB CST,0.85,Accept,Experimental Usage,MAP2,,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Anti-β3-Tubulin antibody primary IF and WB CST,0.85,Accept,Experimental Usage,β3-Tubulin,,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Anti-GFAP antibody primary IF and WB CST,0.85,Accept,Experimental Usage,GFAP,,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Anti-NF-200 antibody primary IF and WB CST,0.85,Accept,Experimental Usage,NF-200,,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Anti-NeuN antibody primary IF and WB CST,0.85,Accept,Experimental Usage,NeuN,,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Anti-cleaved caspase-3 antibody primary IF and WB CST,0.85,Accept,Experimental Usage,cleaved caspase-3,,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Anti-neurofibromin antibody primary WB CST,0.9,Accept,Experimental Usage,neurofibromin,,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Anti-P-mTOR antibody primary WB CST,0.85,Accept,Experimental Usage,P-mTOR,,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Anti-Rictor antibody primary WB CST,0.85,Accept,Experimental Usage,Rictor,,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Anti-GAPDH antibody primary WB CST,0.85,Accept,Experimental Usage,GAPDH,,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Anti-Bcl-2 antibody primary IF and WB CST,0.85,Accept,Experimental Usage,Bcl-2,,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Anti-CNPase antibody primary IF and WB CST,0.85,Accept,Experimental Usage,CNPase,,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Anti-myelin basic protein (MBP) antibody primary IF and WB CST,0.85,Accept,Experimental Usage,myelin basic protein,,,,,,
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,"cleaved caspase-3+ cells (1∶500 dilution; Cell Signaling Technology, Beverly MA)",0.85,Accept,Experimental Usage,cleaved caspase-3,Unknown,Unknown,,,,
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,stained with pErbB2 (1∶50 dilution) as previously described [14],0.85,Accept,Experimental Usage,pErbB2,Unknown,Unknown,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"BLBP (1:2000, rabbit, a kind gift from Dr. Todd Anthony)",0.9,Accept,Experimental Usage,BLBP,Rabbit,Unknown,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"Calbindin (1:1000, mouse, Sigma-Aldrich)",0.9,Accept,Experimental Usage,Calbindin,Mouse,Unknown,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"GFAP (1:2000, rabbit, DAKO, Carpinteria, CA)",0.9,Accept,Experimental Usage,GFAP,Rabbit,Unknown,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"BrdU (1:1000, rat, Abcam, Cambridge, MA)",0.9,Accept,Experimental Usage,BrdU,Unknown,Unknown,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"NeuN (1:400, mouse, Millipore, Billerica, MA)",0.9,Accept,Experimental Usage,NeuN,Mouse,Unknown,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"GABARα6 (1:500, rabbit, Millipore)",0.9,Accept,Experimental Usage,GABARα6,Rabbit,Unknown,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"Ki-67 (1:500, mouse, BD Pharmingen)",0.9,Accept,Experimental Usage,Ki-67,Mouse,Unknown,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"Tbr2 (1:1000, rabbit, Abcam)",0.9,Accept,Experimental Usage,Tbr2,Rabbit,Unknown,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"Calretinin (1:1000, mouse, Millipore)",0.9,Accept,Experimental Usage,Calretinin,Mouse,Unknown,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"MAP2 (1:1000, mouse, Sigma-Aldrich)",0.9,Accept,Experimental Usage,MAP2,Mouse,Unknown,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"P27 (1:250, rabbit, Santa Cruz Biotechnology, Dallas, TX)",0.9,Accept,Experimental Usage,P27,Rabbit,Unknown,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"β-gal (1:1000, rabbit, 5 prime-3 prime, Gaithersburg, MD)",0.9,Accept,Experimental Usage,β-gal,Rabbit,Unknown,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"p-Erk (1:200, rabbit, Cell Signaling, Beverly, MA)",0.9,Accept,Experimental Usage,p-Erk,Rabbit,Unknown,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"p-S6 (1:1000, rabbit, Cell Signaling)",0.9,Accept,Experimental Usage,p-S6,Rabbit,Unknown,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"Nf1 (1:1000, rabbit, Upstate, Lake Placid, NY)",0.9,Accept,Experimental Usage,Nf1,Rabbit,Unknown,,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,"Antibodies: anti-human C-terminal BIM (goat, Bio-RAD, Hercules, CA, USA, AHP2074; 1:1000)",0.9,Accept,Experimental Usage,BIM,Unknown,Polyclonal,,,Human,Non-conjugated
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,"anti-human N-terminal BIM (C34C5) (rabbit, Cell Signaling, #2933; 1:1000)",0.9,Accept,Experimental Usage,BIM,Rabbit,Monoclonal,,,Human,Non-conjugated
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,"anti-b-tubulin (mouse, Developmental Studies Hybridoma Bank E7, Iowa City, IA USA, 1:10,000)",0.9,Accept,Experimental Usage,b-tubulin,Mouse,Monoclonal,,,,Non-conjugated
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,"S100 mouse monoclonal primary antibody (Cell Signaling Technology, Danvers, USA) diluted 1:1000",0.9,Accept,Experimental Usage,S100,Mouse,Monoclonal,,,Human,Non-conjugated
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,"secondary antibody (1:1000, Anti-Mouse IgG (H+L), F(ab')2 Fragment Alexa Fluor 488 Conjugate, Cell Signaling Technology)",0.9,Accept,Experimental Usage,Mouse IgG,Unknown,Secondary,,,,Alexa Fluor 488
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,"IHC was performed using the Avidin/Biotin blocking kit (Vector Labs, SP-2001) staining with antibodies against S100 (1:250 dilution; catalog ab41548, Abcam)",0.9,Accept,Experimental Usage,S100,Unknown,Unknown,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,"staining with antibodies against S100 (1:250 dilution; catalog ab41548, Abcam), KI-67 (prediluted; catalog 790-4286, Ventana)",0.9,Accept,Experimental Usage,KI-67,Unknown,Unknown,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,"KI-67 (prediluted; catalog 790-4286, Ventana), and COL4A (1:1000 dilution; catalog ab6586, Abcam)",0.9,Accept,Experimental Usage,COL4A,Unknown,Unknown,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,"Immunolabeling for anti-histone H3 (tri methyl K27) (1:200 dilution; catalog ab6002, Abcam)",0.9,Accept,Experimental Usage,histone H3 (tri methyl K27),Unknown,Unknown,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,"The sheared chromatin was immunoprecipitated with 5 μg of anti-XBP1 antibodies (Cell Signaling Technology, Danvers, MA, USA)",0.9,Accept,Experimental Usage,XBP1,Unknown,Unknown,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,"The primary antibodies used in the study include anti-GAPDH (Proteintech Group Inc., Rosemont, IL, USA)",0.9,Accept,Experimental Usage,GAPDH,Unknown,Unknown,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,"anti-α-tubulin (Proteintech Group Inc., Rosemont, IL, USA)",0.9,Accept,Experimental Usage,α-tubulin,Unknown,Unknown,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,"anti-XBP1u (Abcepta, Reservoir Victoria, Australia)",0.9,Accept,Experimental Usage,XBP1u,Unknown,Unknown,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,anti-XBP1s (Cell Signaling),0.9,Accept,Experimental Usage,XBP1s,Unknown,Unknown,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,"anti-Parkin (Cell Signaling, Danvers, MA, USA)",0.9,Accept,Experimental Usage,Parkin,Unknown,Unknown,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,"anti-PINK1 (Genetex, Hsinchu, Taiwan)",0.9,Accept,Experimental Usage,PINK1,Unknown,Unknown,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,"anti-LC3B (Cell Signaling, Danvers, MA, USA)",0.9,Accept,Experimental Usage,LC3B,Unknown,Unknown,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,"anti-GLUT1 (Proteintech Group Inc., Rosemont, IL, USA) antibodies",0.9,Accept,Experimental Usage,GLUT1,Unknown,Unknown,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,"the primary antibodies, anti-ATP5H (Thermo Fisher Scientific, Waltham, MA, USA)",0.9,Accept,Experimental Usage,ATP5H,Unknown,Unknown,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,"anti-LC3 antibodies (Cell Signaling, Danvers, MA, USA)",0.9,Accept,Experimental Usage,LC3,Unknown,Unknown,,,,
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,"proliferation marker protein Ki-67 (antigen Ki67, monoclonal mouse anti-human Ki67 antigen, clone MIB1, M7240, DAKO)",0.95,Accept,Experimental Usage,Ki67,Mouse,Monoclonal,,,Human,
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,"cyclin-dependent kinase inhibitor p21 (p21, monoclonal mouse anti-human p21 WAF1/Cip1 , M7202, DAKO)",0.95,Accept,Experimental Usage,p21,Mouse,Monoclonal,,,Human,
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,"tumor protein p53 (p53, monoclonal mouse anti-human p53 M7001, DAKO)",0.95,Accept,Experimental Usage,p53,Mouse,Monoclonal,,,Human,
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,"B-cell lymphoma 2 (bcl2, monoclonal mouse anti-human bcl2 oncoprotein, M887, DAKO)",0.95,Accept,Experimental Usage,bcl2,Mouse,Monoclonal,,,Human,
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,"B-cell lymphoma 6 (bcl6, monoclonal mouse anti-human bcl6 protein, M7211, DAKO)",0.95,Accept,Experimental Usage,bcl6,Mouse,Monoclonal,,,Human,
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,"cyclin D1 (monoclonal rabbit anti-human cyclin D1, M3642, DAKO)",0.95,Accept,Experimental Usage,cyclin D1,Rabbit,Monoclonal,,,Human,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,"incubated with phospho-RB1 S807/811 antibody (Cell Signaling Technology, no. 8516, 1:1600)",0.9,Accept,Experimental Usage,phospho-RB1 S807/811,Unknown,Unknown,,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,"kappa light chain to identify plasma cells (rabbit monoclonal antibody, Sigma Aldrich, clone RM103, SAB5600201, 1:400)",0.9,Accept,Experimental Usage,kappa light chain,Rabbit,Monoclonal,,,Mouse,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,"B220 to identify B cells (RRID: AB_323211, rat anti-mouse monoclonal, Serotec Company, Catalog #MCA1258G, 1:1200)",0.9,Accept,Experimental Usage,B220,Unknown,Monoclonal,,,Mouse,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,"CD3 to identify T cells (rabbit monoclonal, NeoMarkers Company, #RM-9107-S, 1:200)",0.9,Accept,Experimental Usage,CD3,Rabbit,Monoclonal,,,Mouse,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,Immunostaining for SIAH (24E6H3 mouse monoclonal antibody),0.85,Accept,Experimental Usage,SIAH,Mouse,Monoclonal,,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,Immunostaining for SIAH (24E6H3 mouse monoclonal antibody) and RABL6A was conducted,0.85,Accept,Experimental Usage,RABL6A,Unknown,Unknown,,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,bi-weekly intraperitoneal injections of 10 mg/kg anti-PDL1 antibody (BioXCell BE0101),0.9,Accept,Experimental Usage,PD-L1,Unknown,Unknown,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,"stained for Ref-1 (mouse Ref-1 antibody, 1:200 dilution, Novus Biologicals, 13B8E5C2)",0.95,Accept,Experimental Usage,Ref-1,Mouse,Monoclonal,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,"p-STAT3 (Y705) (rabbit monoclonal 1:25 dilution, Cell Signaling, D3A7)",0.95,Accept,Experimental Usage,p-STAT3,Rabbit,Monoclonal,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,"HIF1-α (rabbit, GTX127309, GeneTex, Irvine, CA, USA)",0.9,Accept,Experimental Usage,HIF1-α,Rabbit,Unknown,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,"STAT3 (mouse, 124H6), Cleaved PARP (poly-ADP ribose polymerase, rabbit, D64E10), total PARP (rabbit, #9542) (Cell Signaling",0.9,Accept,Experimental Usage,STAT3,Mouse,Monoclonal,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,"Cleaved PARP (poly-ADP ribose polymerase, rabbit, D64E10)",0.9,Accept,Experimental Usage,Cleaved PARP,Rabbit,Monoclonal,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,"total PARP (rabbit, #9542) (Cell Signaling, Danvers, MA, USA)",0.9,Accept,Experimental Usage,PARP,Rabbit,Unknown,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,"Vinculin (mouse, V284, Sigma, St. Louis, MO, USA)",0.9,Accept,Experimental Usage,Vinculin,Mouse,Unknown,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,"Actin (mouse, ACTN05(C4), NeoMarkers) at 1:1000 dilution",0.9,Accept,Experimental Usage,Actin,Mouse,Monoclonal,,,,
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,"The absence of merlin in schwannoma cells was confirmed regularly by Western blot (1:2000, Cat. No. 12888, Cell Signaling Technology)",0.9,Accept,Experimental Usage,merlin,Unknown,Unknown,,,,
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,"Cells were stained with antibodies specific for Ki-67 (1:800 dilution, Cat. no. 9449, Cell Signaling)",0.9,Accept,Experimental Usage,Ki-67,Unknown,Unknown,,,,
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,in-house developed antibodies specific for Hsp90 nitrated at Tyr 33 or Tyr 56 (dilution 1:200),0.95,Accept,Experimental Usage,nitrated Hsp90,Unknown,Unknown,,,,
